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Type 1 Diabetes Mellitus (T1DM) is a chronic disease caused by an auto-immune 
response where the insulin producing cells in the pancreas are destroyed. Patents with 
T1DM do not produce any insulin; consequently, they must inject insulin and monitor 
blood glucose levels manually to attempt to maintain glycemic homeostasis. There is no 
cure for T1DM. Patients must focus on maintaining blood glucose levels to prevent 
morbidity from the disease. However, even tight control of blood glucose levels does not 
eliminate the risk of morbidity, and acute complications are common, especially in early 
childhood and adolescence. The high doses of injected insulin required to maintain 
glycemic homeostasis in T1DM patients put them at high risk of severe hypoglycemia 
(SH). Inadequate insulin, frequently caused by illness, is the primary cause of diabetic 
ketoacidosis (DKA).  
The purpose of this dissertation was to describe demographics, initial care, and 
treatment patterns among T1DM patients and to estimate the effects of different treatment 
modalities on glycemic control and utilization of emergency care. We used insurance 
claims and electronic medical records (EMR) from the Department of Defense (DOD) 
Military Health Systems (MHS) database to create a cohort of pediatric T1DM patients, 
though different subsets of patients were used for each Aim depending on the 
requirements of each analysis. For the purposes of these analyses, a switch was defined as 
a change in insulin delivery method from multiple daily injections (MDI) to continuous 
subcutaneous insulin infusion (CSII) and an augment was defined as addition of a 
continuous glucose monitor (CGM) to self-monitoring of blood glucose (SMBG). 
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The first Aim focused on describing an incident cohort of T1DM patients. We 
found over 96% of patients in our cohort were using conventional therapy, consisting of 
MDI and SMBG, three months after diagnosis. During follow-up, more than half of 
patients switched insulin delivery to CSII, and about a third augmented with CGM. 
Nearly every patient who used a CGM had previously initiated CSII. Female gender, 
higher military rank of sponsor, and residing in the Central US were associated with a 
treatment change. We tested for trends in CSII and CGM use over time and found 
calendar year of T1DM diagnosis was not associated (p=0.78) with CSII use; however, 
CGM use significantly increased (p<0.0001) during the study period. 
In Aim 2, we estimated the effect of a treatment change on the next hemoglobin 
A1c measurement. We found there was no interaction between switch and augment 
(p=0.93); however, changes in hemoglobin A1c after a switch or augment were depended 
on the A1c level before the treatment change. Improvements in hemoglobin A1c after a 
treatment change were, on average, higher among patients with poorer glycemic control. 
We estimated that patients with an initial hemoglobin A1c of 6% experienced no effect 
from a switch or augment. However, a patient with an initial A1c of 9% would 
experience a reduction of 0.55% (p<0.0001) from a switch and 0.30% (p=0.002) from an 
augment, and a patient with a hemoglobin A1c of 12% would experience a reduction of 
1.13% (p<0.0001) from a switch and 0.51% (p=0.007) from an augment. 
The purpose of the Aim 3 was to estimate differences in total emergency care 
utilization among patients initiating CSII and/or CGM compared to patients using MDI 
and/or SMBG. We observed 2.15 total emergency care days per patient year of follow-
up. We estimated that CSII (RR = 0.81; p<0.0001) and CGM (RR = 0.88; p<0.0059) 
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decreased total emergency care days among patients initially using conventional therapy. 
Patients using both CSII and CGM experienced no additional benefit compared to those 
using CSII (with SMBG) or CGM (with MDI). CSII and CGM therapy were associated 
with a reduction in ER/ambulance days as well as hospitalization days. A secondary 
analysis of the effects of CSII and CGM on diabetes-related emergency care showed 
treatment choices may play an important role in both diabetes-related and total 
emergency care utilization. 
Overall we found a substantial proportion of patients utilizing CSII and CGM. 
Changes in treatment were associated with reductions in hemoglobin A1c and decreased 
utilization of emergency care. Pediatric T1MD patients using conventional therapy who 
struggle to attain hemoglobin A1c levels less than 7.5%, the level of glycemic control 
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CHAPTER 1: INTRODUCTION 
The purpose of this dissertation is to describe incident type 1 diabetic patients in 
terms of demographics, initial care, and treatment patterns and to asses if treatment 
choices affect glycemic control (hemoglobin A1c) and utilization of emergency care. 
This will provide valuable data that is currently unavailable. Our hope is the results of the 
study will help inform clinicians, patients, researchers, and policy makers about patterns 
of T1DM treatments and their effects on glycemic control. 
 
Background 
Type 1 Diabetes: 
Diabetes mellitus is a chronic syndrome of impaired carbohydrate, protein, and fat 
metabolism due to insufficient production of the hormone insulin. The disease manifests 
in two main types. Type 1 Diabetes Mellitus (T1DM) is a chronic disease caused by an 
auto-immune response where the insulin producing cells in the pancreas are destroyed. 
Type 2 diabetes mellitus (T2DM) is typically caused by insulin resistance or reduced or 
delayed insulin production. T2DM patients may be able to control the disease by diet 
alone but medication is often necessary. Unlike T2DM, people with T1DM do not 
produce any insulin. As a result, T1DM patients must inject insulin several times daily to 
control their blood glucose levels. There is no cure for T1DM; therefore, patients must 
focus on maintaining blood glucose levels in order to prevent morbidity from the 
disease.
1
 However, even tight control of blood glucose levels does not eliminate the risk 
of complications. 
To maintain control over blood glucose levels, Type 1 diabetics must inject 
insulin, take multiple blood sugar readings daily, closely monitor their diet, and maintain 
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a healthy lifestyle. They must balance caloric intake with current blood sugar levels and 
expected daily exercise when determining how much insulin to take. Even small 
miscalculations in insulin dosages can result in high or low blood sugars. Consequently, 
most T1DM patients struggle or fail to maintain glycemic control.  
Hemoglobin A1c measures a person’s average blood sugar over the preceding 
three months and is the standard measure of long term glycemic control. Normal 
hemoglobin A1c levels for non-diabetic persons range from 4 to 6%, indicating average 
blood sugars of 70 to 126 mg/dL, respectively. The American Diabetes Association 
(ADA) recommends pediatric patients maintain a hemoglobin A1c of 7.5% or less.
2
 A 
2011 study of nearly 21,000 T1DM patients found the average hemoglobin A1c to be 
8.18%, suggesting the average T1DM patient has an average blood sugar of 214 mg/dL.
3
 
Maahs et al. recently found that only 22% of US children are meeting the current ADA 
goal.
4
 Studies have shown that fear of hypoglycemia is a major contributor to difficulties 
reaching hemoglobin A1c goals.
5,6,7
 
Though most low blood sugar events are mild and easily corrected by eating or 
drinking carbohydrates with a high glycemic index, severely low blood sugar levels can 
be acutely dangerous leading to unconsciousness, coma, and even death. Multiple 
episodes of severe hypoglycemia (SH) can result in seizures, cardiovascular disease, and 
cognitive decline.
8


















There are approximately 1 million people in the Unites States living with type 
1diabetes, and the economic burden is estimated at nearly $15 billion annually.
14
 The 
CDC estimates between 2002 and 2005, there were 15,600 incident cases of T1DM 
annually in people under the age of 20 in the US.
15
 Globally, the incidence of T1DM is 
increasing by 2 to 4% annually. Though incidence of T1DM was steady in the US from 
1980’s through the 1990’s, recent research estimates incidence has been increasing by 
2.3% annually since 2000.
16
 Simulations have projected the prevalence of type 1 diabetes 
among US children may double or triple by the year 2050.
17
 The causes behind the 
increasing trend in global incidence are unknown.
18
 
The majority of type 1 diabetic patients will suffer morbidities from the disease. A 
US study found after 30 years of T1DM, 50% of patients reported retinopathy, 25% 
reported kidney disease, and 14% reported cardiovascular disease.
19
 A Polish study found 
among individuals with at least a 20 year history of T1DM, only 1 in 10 patients was free 
of any microvascular complication.
20
 Studies have generally estimated the standardized 
mortality ratios (SMRs) of T1DM patients to be between 2 and 5, and a Norwegian study 




Modes of Treatment: 
Treatment for type 1 diabetes involves injecting insulin subcutaneously and 
monitoring blood glucose levels. Methods for injecting insulin include multiple daily 
injections (MDI) and continuous subcutaneous insulin infusion (CSII), also known as an 
insulin pump. Patients who treat with MDI typically inject a long acting (basal) insulin as 
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a base as well as rapid-acting (bolus) insulin for meals and high blood glucose correction. 
Patients using CSII use only rapid-acting insulin. The pump is programmed to 
continuously deliver insulin at a programmed basal rate and will deliver bolus insulin for 
meals or blood glucose correction when manually instructed to do so. Methods for 
monitoring blood glucose levels include self- monitoring of blood glucose (SMBG) and 
use of a continuous glucose monitor (CGM). SMBG is achieved by pricking one’s finger 
multiple times daily to measure a blood glucose level. A CGM is a device that is attached 
to the patient and continuously reads glucose levels in interstitial fluid using a wire sensor 
inserted in the skin. While all T1DM patients are advised to make insulin dosing 
decisions based on finger stick blood sugars, CGM can be used to estimate blood glucose 
as well as indicate whether glucose levels are increasing, decreasing, or remaining steady.  
 
Effectiveness of Treatment Modalities: 
Studies measuring the effects of CSII and/or CGM usage compared to 
conventional therapy (injections and finger stick blood sugars) on glycemic control have 
demonstrated mixed results. A recent systematic review comparing MDI with CSII 
concluded there was no difference in hemoglobin A1c levels among children, though 
adults’ A1c levels were on average 0.3% lower with CSII.
22
 However, studies suggest 
there may be decreased risk of ketoacidosis and severe hypoglycemia among patients 
using CSII.
 23,24,25
 Clinical trials of CGM in children have generally not demonstrated 
clinically meaningful differences in glycemic control except in those with strict 
adherence or high hemoglobin A1c levels at baseline.
26,27 
Evidence of the effectiveness of 
CGM use at reducing risk of acute complications of T1DM is mixed, with some studies 
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suggesting a reduction in SH and/or DKA
28,29,30
 and some finding no association.
31,32
 
Trials of sensor augmented insulin pumps (a system containing CSII integrated with a 
CGM) have consistently shown improvement in hemoglobin A1c, mean blood sugar, and 




Identifying patients in EMR/Claims databases: 
Pharmacoepidemiological studies utilize electronic medical record (EMR) and 
insurance claims databases as time and cost-efficient sources of patients and medical 
information for public health research. These studies typically rely on International 
Classification of Diseases, Ninth Revision (ICD-9) codes to detect and differentiate 
diseases. ICD-9 codes have been shown to have a high positive predictive value when 
identifying T1DM patients.
36
 Several studies have developed algorithms including patient 
demographics, laboratory measures, medical encounters, and prescription data to identify 
pediatric diabetic patients and differentiate between T1DM and T2DM patients.
37,38,39,40 
These studies have been able to achieve algorithms with high sensitivity, specificity, and 
positive predictive value.  
 
Significance 
The treatment patterns of pediatric type 1 diabetic patients are not well described 
in the literature. Aim 1 of this dissertation was designed to identify and describe a 
pediatric cohort with incident type 1 diabetes. Patients were identified using a data driven 
algorithm designed to identify T1DM patients with high specificity. We were able to 
follow these patients through time and observe changes in treatment as they occurred.  
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The purpose of Aim 2 and Aim 3 was to estimate the effects of changing 
treatment (switching to CSII and/or augmenting with CGM) on measures of glycemic 
control. Most studies describing these therapies are clinical trials and are generally 
designed to answer the question: Do patients initiating CSII and/or CGM experience 
improved glycemic control compared to patients who continue to use conventional 
therapy? These trials are designed to measure the treatment effects associated with a CSII 
and/or CGM. However, patient experiences may differ from the estimated true effects. 
Changes in glycemic control measured in observational studies equal the sum of the true 
treatment effects and other influences, such as patient motivation and adherence. We, 
therefore, attempted to answer a slightly different question: Do patients who initiate CSII 
and/or CGM in a typical care setting experience subsequent improvements in glycemic 
control? This is an important question as effects of treatment experience outside a trial 
setting could theoretically be larger or smaller than predicted. Our goal was to estimate 




Specific Aim 1: Describe characteristics at presentation, treatment patterns, predictors of 
treatment modality, trends in treatment over time, and switching and augmentation 
patterns in a pediatric population with incident T1DM using data from the Department of 





Specific Aim 2: Estimate changes in hemoglobin A1c after initiation of CSII and/or CGM 
compared to changes in hemoglobin A1c among patients who continue using MDI and/or 
SMBG in a pediatric population with T1DM for at least a year using data from the 
Department of Defense Military Health Systems electronic medical record and insurance 
claims database. 
 
Specific Aim 3: Estimate changes in emergency care utilization after initiation of CSII 
and/or CGM compared to changes in emergency care utilization among patients who 
continue using MDI and/or SMBG in a pediatric population with T1DM for at least a 
year using data from the Department of Defense Military Health Systems electronic 
medical record and insurance claims database. 
 
Conceptual Framework 
The Aims in this dissertation are organized so each subsequent Aim builds on the 
results of the work preceding it. In Aim 1, T1DM patients will be identified and 
described in terms of treatment patterns and associated characteristics. Aim 2 will use the 
information gathered in Aim 1 to build a model that will attempt to estimate differences 
in hemoglobin A1c subsequent to a change in treatment. Aim 3 will take this a step 
further by trying to estimate if treatment changes effect emergency care utilization. The 
conceptual framework is displayed in Figure 1 and the main analyses of each Aim are 












All patients included in this study had type 1 diabetes based on an algorithm we defined during 
exploratory analysis: at least two T1DM medication orders on separate days and (at least one T1DM 
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CHAPTER 2: MANUSCRIPT 1 – TREATMENT PATTERNS 
 
Abstract 
Purpose: The purpose of this study was to identify an incident cohort of pediatric 
patients with type 1 diabetes mellitus (T1DM) and to describe their medical and 
demographic characteristics, treatment patterns, and predictors of treatment at diabetes 
presentation and during follow-up. 
Methods: This study was performed using data extracted from the US Department 
of Defense (DOD) Military Health Systems (MHS) database between October 2007 and 
September 2013. Exploratory analyses were performed to develop an algorithm designed 
to identify diabetic patients and differentiate between type 1 and type 2 diabetes. Patients 
were described in terms of medical and demographic characteristics and treatment 
patterns. We performed Kaplan Meier and Cox proportional hazards analyses to estimate 
characteristics predictive of continuous subcutaneous insulin infusion (CSII) and 
continuous glucose monitor (CGM) use. 
Results: We identified 1,953 pediatric patients with incident type 1 diabetes as 
defined by our algorithm. The majority (96.3%) of patients in our cohort used 
conventional therapy at type 1 diabetes presentation. Survival analysis showed more than 
half (57.1%) of patients initiated CSII and about a third (32.62%) initiated CGM during 
follow-up. Most (81%) patients who initiated CGM did so at the same time or after 
initiating CSII. We found younger age (p<0.0001), female gender (p<0.0001), and higher 
military rank of sponsor (p<0.0001) were independently associated with a treatment 
switch or augment. In multivariate analyses, previous use of CGM was the best predictor 
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of CSII initiation (HR=2.5; [95% C.I., 1.74 – 3.30]), and previous use of CSII was the 
best predictor of CGM use (HR=22.79; [95% C.I., 18.13 – 28.64]). We tested for trends 
in CSII and CGM use over time and found calendar year of T1DM diagnosis was not 
associated (p=0.78) with CSII use; however, CGM use significantly increased (p<0.0001) 
during the study period. 
Conclusion: We were able to identify an incident cohort of type 1 diabetic 
patients and describe their treatment patterns and associated characteristics. Initiation of 
CSII and CGM was common in this young cohort of patients with T1DM. More research 
would be needed to determine if the treatment patterns we observed are typical of other 




Type 1 diabetes mellitus (T1DM) is one of the most important pediatric chronic 
diseases in the United States, affecting more children than cancer.
1
 Today, approximately 
1 million people in the United States are living with T1DM,
2
 with roughly one in 500 
children affected.
3
 Research indicates that T1DM incidence is rapidly increasing
4,5,6
 and 
that the prevalence among US children may double or triple by the year 2050.
7
  
Type 1 diabetes is an auto-immune disease where the insulin producing (beta) 
cells in the pancreas are completely destroyed. Consequently, T1DM patients create no 
insulin of their own and must inject insulin to live. There are two options for injecting 
insulin: multiple daily injections (MDI) and continuous subcutaneous insulin infusion 
(CSII), also referred to as insulin pumps. T1DM patients must also constantly monitor 
blood glucose levels. The two options for monitoring blood glucose include self-
monitoring of blood glucose (SMBG) and use of a continuous glucose monitor (CGM). 
SMBG is achieved by pricking one’s finger multiple times daily to measure a blood 
glucose level. A CGM is a device that is attached to the patient and continuously reads 
glucose levels in interstitial fluid using a wire sensor inserted in the skin.  
Continuous subcutaneous insulin infusion more closely imitates the body’s 
natural metabolic processes compared to multiple daily injections. The benefits of using 
CSII include improved quality of life and reduced glycemic variability, and possibly, 
reduced risk of severe hypoglycemia and diabetic ketoacidosis.
8,9
 Patients who use CSII 
demonstrate much higher treatment satisfaction compared to those using MDI.
10,11
 CSII 
has also been shown to reduce daily insulin requirements by 21%.
12
 Yet barriers to CSII 
persist, including negative patient perceptions
13





evidence that CSII (compared to MDI combining fast and long-acting insulins) reduces 
hemoglobin A1c is mixed.
16,17,18
 
Continuous glucose monitoring offers several benefits over self-monitoring of 
blood glucose. While a single finger prick blood sugar gives the glucose reading for a 
single point in time, a CGM provides a reading every few minutes so patients may more 
easily recognize patterns and trends throughout the day. Furthermore, because glucose 
readings are continuous, a CGM may warn patients of high or low blood sugars via preset 
alarms before they would have otherwise known. Patients using CGM have reported less 
fear of hypoglycemia and improved empowerment and quality of life.
19
 However, clinical 
trials have not shown meaningful improvements in hemoglobin A1c in pediatric 
populations,
20,21,22
 or reductions in severe hypoglycemic events,
23
 though they have 
demonstrated reduced time in hypoglycemia (blood glucose < 70 mg/dL).
24
 
Despite the potential benefits of CSII and CGM, many patients continue to use 
conventional therapy (MDI and SMBG). Motivations for treatment choices among 
T1DM patients are not well studied; though, it is likely that reluctance to use CSII and 
CGM is largely due to high associated costs of treatment, invasiveness, and perceived 
body image and social acceptance.
25,26,27,28
 Manufacturer data from 2006 suggested 
nearly a quarter of type 1 diabetic patients in the United States were using CSII.
29
 
However, to our knowledge, there have been no studies describing treatment patterns in 
pediatric T1DM populations in the United States. The primary objective of this study was 
to identify a cohort of incident pediatric T1DM patients and describe their treatment 
patterns at first diagnosis and during follow-up. We also aimed to describe our cohort in 
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terms of medical and demographic characteristics at disease presentation and estimated 




This study was performed using data extracted from the US Department of 
Defense (DOD) Military Health Systems (MHS) database. The DOD MHS serves active 
and past military personnel (known as the sponsor) and their dependents. The database 
includes both an electronic medical record (EMR) and a medical insurance claims 
component. All patients are included in the insurance claims data, and approximately one 
third have EMR data. Data collected includes: demographics, diagnostic codes, 
information on medical procedures, symptoms, vital signs, laboratory and radiology 
results, and pharmacy orders and claims. The crude data, prepared by Health Research Tx 
(HRTx), included all EMR encounters and insurance claims for patients with at least one 
International Classification of Diseases, Ninth Revision (ICD-9) diagnostic code 
indicating diabetes (250.XX) before their 19
th
 birthday. All personally identifiable 
information was removed. At the time of extraction, data were available between October 
2007 and September 2013. Our first objective was to use these data to create a cohort of 
patients with incident T1DM.  
Patients in the DOD MHS dataset during the study period meeting the following 
criteria were selected for this study: 
 At least one of the following: 
o One hospitalization with an ICD-9 diagnostic code for DM (250.XX) 
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o Two DM diagnostic codes within one year 
o One diagnostic code for DM and one treatment for DM 
 Age 18 years or younger at first diabetes diagnosis 
 A minimum of 6 months of enrollment (baseline period) before first DM 
diagnosis 
 A minimum of 4 months of enrollment after first DM diagnosis 
Among patients meeting the eligibility criteria, the first day where an eligible patient 
had a diabetes-related ICD-9 (250.XX) or medication was considered the index day for 
the study. The requirement for a 6-month baseline enrollment period before the index day 
was designed to help create a cohort with new onset diabetes. We required at least 4 
months of follow-up to allow time for measurement of treatment patterns after diabetes 
presentation. 
Exclusion criteria were chosen to reduce the number of patients with gestational or 
other secondary (non-type 1 or 2) diabetes. Patients meeting the following criteria were 
excluded from the study: 
 Patients becoming pregnant less than four months after index date were excluded. 
(Patients becoming pregnant greater than four months after index were censored 
at the pregnancy date.)  
 Patients with an ICD-9 code indicating any of the following: secondary diabetes 
(249.x), other endocrine dysfunction (251.8), adrenal cortical steroids causing 
adverse effects in therapeutic use (E932.0), adenocarcinomas (151.0), lupus 
erythematosus (710.0, 695.4), cystic fibrosis (277.0, 277.0X), hemochromatosis 
(275.0), acromegaly (253.0), Cushing’s syndrome (255.0),  own syndrome 
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(758.0), Klinefelter syndrome (758.7), Turner syndrome (758.6), Huntington 
chorea (333.4), or Laurence-Moon-Biedl syndrome (759.89). 
 
Diabetes Type Algorithm 
Previous studies have shown T1DM diagnostic codes and insulin prescriptions 
can be used to identify pediatric T1DM patients in claims and EMR data with high 
specificity.
30,31,32,33
 Using this information, we performed exploratory data analyses to 
develop an algorithm to differentiate between type 1 and type 2 diabetes in the MHS data. 
To achieve this, we created a cohort of patients with only type 1 (250.x1or 250.x3) or 
with only type 2 (250.x2) ICD-9 diagnostic codes. The characteristics of these patients 
were used to differentiate between diabetes types for those patients where diagnostic 
codes were of mixed type or only included unspecified diabetes (250.00). 
 
Mode of Diabetic Treatment  
Patients identified as T1DM were described in terms of initial treatment. As it can 
take several weeks for insurance companies to approve CSII or CGM usage, initial 
treatment was defined as the treatment a patient was using 90 days after the index day. 
Patients were divided into the following four groups: 
 MDI and SMBG (conventional therapy) 
 MDI and CGM 
 CSII and SMBG 
 CSII and CGM 
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For the purposes of this study, a treatment “switch” was defined as a change in insulin 
delivery method, from multiple daily injections to continuous subcutaneous insulin 
infusion. An “augment” was defined as initiation of CGM, as CGM use is meant to be in 
addition to self-monitoring of blood glucose. We described switching and augmentation 
patterns among those patients using conventional therapy at index. 
 
Statistical Analyses 
After diagnosis, patients with type 1 diabetes frequently experience a temporary 
period of partial remission called the “honeymoon period” where the pancreas continues 
to secrete a small amount of insulin.
34
 Because we hoped to identify an incident cohort, 
we hypothesized that hemoglobin A1c values for the study population should fall sharply 
after index and then rise again as the honeymoon period, and thus endogenous insulin 
secretion, ends. We created a Lowess plot of hemoglobin A1c over time to determine if 
we could observe this phenomenon. 
We created means and frequency distributions of patient characteristics to 
describe the study population as a whole and by index treatment group. We calculated 
statistical significance of continuous variables using a t-test and significance of binary 
and categorical variables using a chi square statistic.  
We estimated differences in time to switch/augment by gender and year of 
diagnosis by Kaplan Meier analysis using a Log-Rank test for the statistical significance 
of differences between groups. Finally, we created a multivariate Cox Proportional 
Hazards (CPH) model using backwards selection from variables significantly associated 
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with switch/augment in bivariate analyses. Separate models were created for time to 
initiation of CSII and time to initiation of CGM using claims and EMR data. 
 




Diabetes Type Algorithm 
A total of 3,757 patients were eligible for this study (see Figure 1); however, 
diabetes type for these patients was unknown. We found 94% of patients with only type 1 
ICD-9 codes had multiple medication orders for insulin, while 82% of patients with only 
type 2 codes had none. The final differentiating algorithm [at least two T1DM medication 
orders on separate days and (at least one T1DM diagnostic code or zero T2DM diagnostic 
codes)] identified 1,953 algorithm-defined T1DM patients.  
 
Patient Characteristics 
Our study population consisted of 1,953 individuals including 1,071 males and 
882 females. The average age at T1DM presentation was 12.4 years old. Among patients 
with EMR data, the average hemoglobin A1c at index was 11.6% and the average BMI 
was 20.1 kg/m
2
. Hospitalizations were rare during the 6-month baseline period; however, 
14.2% of patients visited the emergency room during this time. The index therapy for 
nearly all (n=1,881; 96.3%) patients was MDI and SMBG (conventional therapy); few 
patients used CSII and SMBG (n=62; 3.2%), MDI and CGM (n=3; 0.2%), or CSII and 
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CGM (n=7; 0.4%) within the first three months after index. Patient characteristics by 
index treatment group (MDI vs. CSII) are displayed in Table 1. At T1DM presentation, 
59.2% of patients received care in the emergency room and 65.3% were hospitalized. 
Younger patients were more likely to be hospitalized (p<0.0001) compared to older 
patients (See Table 2). Patient selection and treatment patterns at index and follow-up are 
displayed in Figure 1. 
 
Hemoglobin A1c 
The average hemoglobin A1c during the duration of the study was 8.8%. The 
Lowess plot of hemoglobin A1c clearly showed the effects of uncontrolled 
hyperglycemia at index followed by the honeymoon period. The plot predicted a decrease 
in A1c from 12.2% at T1DM presentation to 7.2% three months later. Average A1c 
values then steadily increased until stabilizing at around 8.7% approximately 12 to 14 
months after presentation. The average hemoglobin A1c after the first year of diabetes 
was 8.7%. The Lowess plot of hemoglobin over time is displayed in Figure 2. 
 
Treatment Patterns at T1DM Presentation 
Because so few (n=10) patients were using a CGM at index, we were unable to 
test the statistical significance of differences between them and patients using SMBG. 
However, we were able to evaluate differences between CSII users (n=69) and patients 
using MDI (n=1,884). CSII users were more likely to be female (p=0.029), had lower 
BMI (p=0.048), higher military rank of sponsor (p=0.028), were less likely to visit the 
ER during baseline (p=0.0.004), less likely to visit the ER at index (p=0.001), and less 
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likely to be hospitalized (p=0.001) than those using MDI. The difference in index 
hemoglobin A1c was not statistically significant (p=0.29between treatment groups.  
 
Treatment Patterns During Follow-up 
Nearly half (n=813; 43.2%) of patients on conventional therapy at index had a 
change in treatment (initiated CSII and/or CGM) during the study period. Among patients 
who changed treatment, 770 (94.7%) initiated CSII therapy and 319 (39.2%) initiated 
CGM. Very few patients who changed treatment initiated CGM alone (n=43; 5.3%) or 
before beginning CSII (n=19; 2.3%). Thus, the predominate pattern among patients using 
conventional therapy at index who initiated both CSII and CGM (n=276; 14.7%) was for 
patients to initiate CSII and CGM at the same time (n=137; 7.3%) or to add CGM after a 
CSII (n=120; 6.4%). The treatment patterns for patients using conventional therapy at 
index is displayed in Table 3. 
Exploratory analyses showed T1DM patients who chose to switch to CSII were 
characteristically very similar to those who chose CSII and CGM, largely because they 
were the same patients. However, because so few patients (n=42) chose only to augment 
with CGM, we were unable to determine if the characteristics of these patients were 
significantly different than other switch/augmenters. Additionally, we performed a 
sensitivity analysis where augment only patients were removed. There were no 
differences in the number of statistically significantly associated variables between the 
full and the sensitivity analysis models. Therefore, we decided to group switch and 
augmenters together into a single group when analyzing statistical significance of 
predictors of treatment change.  
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In bivariate analyses, patients who changed treatment were more likely to be 
female (p<0.0001), were on average 1.4 years younger at index (p<0.0001), had a mean 
BMI 4.1 kg/m
2
 lower (p<0.0001), higher military rank of sponsor (p<0.0001), were less 
likely to visit the ER during baseline (p=0.008), and were less likely to be hospitalized at 
index (p=0.004) compared to patients who continued using conventional therapy during 
follow-up. While geographic region and military branch were statistically significantly 
associated with a treatment change, the distribution of those variables was not strikingly 
different between treatment change groups. Patient characteristics by treatment change 
group are displayed in Table 4. 
Five years after diabetes presentation, the cumulative proportion of patients who 
had initiated CSII (Figure 3) and CGM (Figure 4) was 57.1% and 32.6%, respectively. 
Analyses demonstrated females were more likely to switch (p<0.001) or augment 
(p=0.006) than males (displayed in Figures 5 and 6, respectively). However, once a 
patient had switched to CSII (Figure 7), there was no association between gender and 
augment (p=0.92). There was no association (p=0.77) between index year and switch to 
CSII (Figure 8); however, there was a strong association between index year and augment 
with CGM (p<0.001). Figure 9 clearly displays that with each successive index year, 
patients augmented with CGM more quickly. 
In multivariate analyses (Tables 5 through 7), patients were more likely to switch 
mode of insulin delivery from MDI to CSII if they had previously used a CGM 
(HR=2.40; p<0.0001), were female (HR=1.28; p=0.0004), or younger in age (HR=0.94; 
p<0.0001). Geographic region (p=0.0079) and higher military rank of sponsor (p<0.0001) 
were also associated with switching. Initiation of CGM was strongly associated with 
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previous CSII use (HR=22.79; p<0.0001) and calendar year of diabetes index (p<0.0001). 
No other variables were predictive of CGM use in this model. Calendar year of diagnosis 
was not associated with initiation of CSII (p=0.78) but was strongly associated with 
CGM. Patients diagnosed with T1DM in 2013 were much more likely to use a CGM 
compared to those diagnosed in 2008 (HR=13.74; p<0.0001). 
Because CSII was so strongly predictive of future CGM use, we performed an 
additional analysis of time to augment restricted to CSII users. In this analysis, 
geographic region (p=0.0483), military branch of sponsor (p=0.0048), and year of 
diabetes index (p<0.0001) were associated with CGM use. Patients who presented with 
T1DM in 2013 were more likely to initiate CGM (HR=4.87; p<0.0001) compared to 
those diagnosed at the beginning of the study. 
Index BMI was associated with initiation of CSII (HR=0.89; p<0.0001) and CGM 
(HR=0.90; p=0.0001) in bivariate analyses; though, index hemoglobin A1c was 
associated with neither. Approximately one fourth (26.2%; n=512) of our cohort had a 
measurement for index BMI. Among these patients, 225 (43.2%) initiated CSII and 83 
(15.9%) initiated CGM. Index BMI (HR=0.89; p= p<0.0001), geographic region 
(p=0.0114), and military rank of sponsor (p=0.0117) were associated with CSII use and 
previous CSII use (HR=27.00; p<0.0001), index BMI (HR=0.94; p=0.0253), and index 
year (p<0.0001) were associated with CGM. Results of the multivariate models using 







Summary of Main Findings 
While the vast majority of patients in our cohort started on conventional therapy 
(96.3%), over half (57.14%) switched insulin delivery from multiple daily injections to 
continuous subcutaneous insulin infusion and about a third (32.62%) augmented with a 
continuous glucose monitor. Nearly every patient who augmented with a CGM, had 
previously initiated CSII. As expected, hemoglobin A1c levels clearly demonstrated a 
“honeymoon period,” falling sharply after diagnosis until month 3, then steadily rising 
until about one year after presentation. The best predictor of CSII initiation was previous 
initiation of CGM; likewise, the best predictor of CGM initiation was previous initiation 
of CSII. Female gender, geographic region, and military rank of sponsor were also 
predictive of CSII. BMI was inversely associated with initiation of CSII and CGM. Year 
of diagnosis was not associated with initiation of CSII (p=0.78); however, CGM use was 
increasing (p<0.0001) during the study period. 
 
Emergency Care at Presentation 
The low frequency of ER admission and hospitalization during the 6-month 
baseline and the high rates of ER admission and hospitalization at index are evidence that 
we correctly identified the first presentation of T1DM. In the United States, the 
prevalence of diabetic ketoacidosis (DKA) at T1DM presentation is estimated to be 
between 25% and 50%.
35
 This is in line with our findings, as post hoc analyses showed 
46.8% of the hospitalizations at index contained an ICD-9 diagnostic code for DKA 
(250.1X) indicating that approximately 31% of our cohort had DKA at presentation. The 
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high rate of DKA and emergency care at diabetes presentation demonstrates that the 
majority of T1DM patients are not identified until they become very ill. 
 
Hemoglobin A1c and BMI 
Approximately 70% of T1 M patients enter a “honeymoon” phase after diagnosis 
where insulin requirements are reduced and glycemic control is increased.
36
 Studies have 
shown that the proportion of patients in honeymoon peaks at approximately 3 months 
after diabetes presentation and then gradually falls so few patients are still in honeymoon 
more than one year after diagnosis.
37,38
 Because we intended to describe treatment 
patterns in an incident cohort, we hypothesized a priori that we should be able to observe 
this phenomenon. This pattern is demonstrated by our Lowess plot of mean hemoglobin 
A1c over follow-up (Figure 1). Furthermore, mean hemoglobin A1c values observed in 
this study are similar to other cohort studies.
39,40,41
  
Symptoms of T1DM begin to appear once 80-90% of pancreatic beta cells are 
destroyed.
42
 As endogenous insulin production decreases, glucose cannot be metabolized 
and is excreted in the urine. Consequently, one of the hallmark symptoms of new onset 
T1DM, along with polyuria and polydipsia, is weight loss,
43,44
 and T1DM patients are 
frequently underweight at presentation.
45,46
 The average BMI among patients in our 
cohort was much lower than would be expected in a healthy pediatric population. The 
hemoglobin A1c and BMI properties of our cohort are further evidence that we were able 





Continuous Subcutaneous Insulin Infusion 
Initiating CSII was associated with increasing military rank of sponsor (our socio-
economic surrogate), younger age at diagnosis, and female gender. These findings are 
consistent with those of other observational studies.
47,48
 It is likely that families with 
higher incomes are better able to afford the high cost of CSII therapy. Also, CSII is 
especially suited for young patients due to the precision needed to administer small 
amounts of insulin and increased parental involvement in disease management compared 
to older adolescents. While it is difficult to speculate why females would be more likely 
to use CSII than males, studies have shown that females have higher hemoglobin A1c 
levels and are more likely utilize emergency care compared to males.
49,50,51
 It may be that 
increased use of CSII in females demonstrates efforts to increase glycemic control, 
though there are likely many other factors involved in treatment choices.  
The first CSII pumps were developed in the late 1970’s,
52,53
 though it was in the 
late 1990’s, after their safety and efficacy had been widely established, when use of CSII 
began rapidly increasing in pediatric populations. 
54,55
 However, in our cohort, we did not 
detect any change in the prevalence of CSII use over time. This suggests that during the 
period from 2008 to 2012 CSII use patterns were stable, at least in our study population.  
 
Continuous Glucose Monitors 
In our cohort, patients initiating CGM consisted primarily of a subset of patients 
using CSII. Consequently, the strongest predictor of initiation of CGM was previous CSII 
use. This observation suggests that motivations for initiation of CGM may be similar to 
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those for initiation of CSII, appealing to the same people. However, to our knowledge, 
there are no studies describing motivations for CGM use. 
The first CGM intended for patient use was approved by the FDA in 2005 and 
became commercially available in 2006. However, no CGM was approved for pediatric 
use until 2014. When designing this study, we were aware of the possibility that we 
would not detect significant CGM use in our cohort as it had not been approved by the 
FDA for this population during the study period. However, we observed nearly one third 
of the patients in our study initiated CGM during the study period demonstrating that off-
label use of CGM was fairly common. We also detected a strong secular trend of 
increasing prevalence for each calendar year during the study period. This trend makes 
sense as CGM therapy is a relatively new, and still improving, technology.   
 
Strengths and Limitations  
Our data suggests we were able to identify an incident cohort of type 1 diabetic 
patients. Identifying the date of T1DM presentation allowed us to measure index 
treatment as well as treatment changes in continuous time during follow-up. This is 
important in situations where more than one treatment combination is possible. For 
example, we observed that initiation of CGM rarely occurs before initiation of CSII. This 
trend would be more difficult to detect among a prevalent T1DM population because 
among patients using both, you would not know which treatment was initiated first. 
This study was completed using EMR and insurance claims data, which has 
several strengths and limitations. Electronic data are readily available and are an efficient 
method for measuring outcomes for large cohorts of patients. Also, using claims data to 
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describe treatment patterns of T1DM patients should capture nearly all insulin, CSII, and 
CGM related purchases as these treatments are expensive and unlikely to be paid for out 
of pocket. EMR data (BMI and/or hemoglobin A1c) was only available for about one 
third of the patients in our cohort. However, at index, having a measurement for BMI 
(p=0.50) or hemoglobin A1c (p=0.15) was not associated with CSII, and having a 
measurement for BMI (p=0.65) or hemoglobin A1c (p=0.14) was not associated with a 
treatment change during follow-up.  
There was likely some misclassification of diabetes type. Identification of patients 
with T1DM was based on algorithms developed during exploratory data analyses. It is 
possible, however, that some T1DM patients were missed and some T2DM patients were 
wrongfully included. Omission of T1DM patients may have reduced statistical power and 
could have resulted in selection bias. Our differentiating algorithm was designed to be 
specific (rather than sensitive), so we believe it is unlikely many patients with T2DM 
were wrongfully classified as type 1. This may reduce generalizability if patients who 
were omitted were characteristically different or would have demonstrated different 
treatment patterns during follow-up. 
Another limitation of EMR/claims data is the lack of information on important 
confounders. For example, we were unable to adjust for sociodemographic indicators, 
including race and ethnicity, in our analyses because this information was missing for 
more than 99% of patients. However, studies have shown socioeconomic characteristics, 
such as higher education and income, are superior predictors of CSII and CGM use 
compared to sociodemographic factors.
56,57,58
 While we did not have household income 
or education data, we were able to use military rank of sponsor in our analysis, which we 
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believed could be a socioeconomic indicator. We observed a strong relationship between 
increasing military rank of sponsor and increased likelihood of CSII/CGM use, which 
supports the hypothesis that rank of sponsor may be a socioeconomic indicator. 
T1DM patients identified in this study may not be representative of the pediatric 
T1DM population in the United States. As the dependents of active and past military 
personnel, patients in this study are likely demographically different than the general US 
pediatric population and likely experience different levels of healthcare. Consequently, 




The purpose of this study was to identify a cohort of patients with incident T1DM 
and to describe patient characteristics at presentation, predictors of treatment, and 
treatment patterns at index and during follow-up. We found 96% of patients were using 
conventional therapy (MDI and SMBG) shortly after diabetes presentation. During 
follow-up, more than half of patients initiated CSII and about a third initiated CGM. Most 
patients who initiated CGM had previously initiated CSII, suggesting that these treatment 
appeal to the same subset of T1DM patients. Calendar year of diagnosis was associated 
with initiation of CGM suggesting that CGM is becoming a more common treatment 
among pediatric T1DM patients. More research is needed to determine if the treatment 
patterns we observed in this study are typical of other T1DM populations. Further, 
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Gender [n (%)]       
    Female 842 (44.7%) 40 (58.0%) 0.029 
    Male 1042 (55.3%) 29 (42.0%)   
Age on Index Day [mean (SD] 12.4 (3.3) 13.0 (3.9) 0.17 
Patients with Index BMI Value [n (%)] 505 (26.8%) 16 (23.2%) 0.5 
    BMI on Index Day [mean (SD)] 20.2 (5.8) 18.3 (3.4) 0.048 
Patients with Index HbA1c Value [n (%)] 283 (15.0%) 6 (8.7%) 0.15 
    HbA1c Value [mean (SD)] 11.6 (2.9) 12.9 (2.8) 0.29 
Year of Diagnosis [n (%)]       
    2008 305 (16.2%) 11 (15.9%) 0.46 
    2009 406 (21.5%) 15 (21.7%)   
    2010 356 (18.9%) 20 (29.0%)   
    2011 372 (19.7%) 9 (13.0%)   
    2012 324 (17.2%) 10 (14.5%)   
    2013 121 (6.4%) 4 (5.8%)   
Military branch [n (%)]       
    Army 822 (43.6%) 31 (44.9%) 0.044 
    Coast Guard 39 (2.1%) 2 (2.9%)   
    Air Force 471 (25.0%) 25 (36.2%)   
    Marine Corps 134 (7.1%) 1 (1.4%)   
    Navy 412 (21.9%) 9 (13.0%)   
    Other 6 (0.3%) 1 (1.4%)   
Geographic region [n (%)]       
    West 190 (10.1%) 3 (4.3%) 0.17 
    Central 293 (15.6%) 14 (20.3%)   
    Northeast 678 (36.0%) 23 (33.3%)   
    Southeast 595 (31.6%) 26 (37.7%)   
    Alaska/Hawaii 80 (4.2%) 0 (0.0%)   
    Non-US 48 (2.5%) 3 (4.3%)   
Rank of Sponsor [n (%)]       
    Enlisted, Junior 124 (6.6%) 4 (5.8%) 0.028 
    Enlisted, Senior 1332 (70.7%) 41 (59.4%)   
    Warrant Officer 59 (3.1%) 3 (4.3%)   
    Officer, Junior 88 (4.7%) 3 (4.3%)   
    Officer, Senior 281 (14.9%) 18 (26.1%)   
Emergency Care During 6-Month Baseline       
    Patients with ER Visits [n (%)] 275 (14.6%) 2 (2.9%) 0.0041 
    ER Days [mean (SD)] 0.2 (0.6) 0.0 (0.2) <0.0001 
    Patients with Hospitalization [n (%)] 19 (1.0%) 1 (1.4%) 0.51 
    Hospitalization Days [mean (SD)] 0.2 (4.5) 0.0 (0.4) 0.096 
Emergency Care at T1DM Presentation       
    Admitted to ER [n (%)] 1128 (59.9%) 28 (40.6%) 0.0014 
    Patients with Hospitalization [n (%)] 1244 (66.0%) 32 (46.4%) 0.0008 
    Hospitalization Days [mean (SD)] 2.5 (2.3) 2.3 (7.3) 0.85 
Table 1 displays characteristics for patients with an index therapy of MDI compared to patients with an 
index therapy of CSII. The index therapy refers to the mode of insulin delivery being used three months 
after T1DM presentation. *We calculated statistical significance of continuous variables using a t-test and 









Number of Patients 








5 17 14 82.4% 
6 38 31 81.6% 
7 73 55 75.3% 
8 122 96 78.7% 
9 182 122 67.0% 
10 191 144 75.4% 
11 221 152 68.8% 
12 177 123 69.5% 
13 185 120 64.9% 
14 161 103 64.0% 
15 158 94 59.5% 
16 150 86 57.3% 
17 144 78 54.2% 








Switch to CSII only 494 (26.3%) 
Augment with CGM only 43 (2.3%) 
Switch and Augment within 90 days 137 (7.3%) 
Switch before augment 120 (6.4%) 
Augment before switch 19 (1.0%) 
No treatment change 1,068 (56.8%) 













Gender [n (%)] 
   
Female 432 (40.4%) 408 (50.2%) <0.0001 
Male 636 (59.6%) 405 (49.8%) 
 
Age on Index Day [mean (SD)] 13.0 (3.1) 11.6 (3.4) <0.0001 
Patients with Index BMI Value [n (%)] 291 (27.2%) 214 (26.3%) 0.65 
Index BMI Value [mean (SD)] 21.9 (6.3) 17.8 (3.8) <0.0001 
Patients with Index HbA1c Value [n (%)] 172 (16.1%) 111 (13.7%) 0.14 
Index HbA1c Value [mean (SD)] 11.5 (3.0) 11.8 (2.7) 0.47 
Year of Diagnosis [n (%)] 
   
2008 137 (12.8%) 167 (20.5%) <0.0001 
2009 194 (18.2%) 212 (26.1%) 
 
2010 180 (16.9%) 176 (21.6%) 
 
2011 215 (20.1%) 157 (19.3%) 
 
2012 237 (22.2%) 85 (10.5%) 
 
2013 105 (9.8%) 16 (2.0%) 
 
Military branch [n (%)] 
   
Army 489 (45.8%) 332 (40.8%) 0.0084 
Coast Guard 20 (1.9%) 19 (2.3%) 
 
Air Force 232 (21.7%) 237 (29.2%) 
 
Marine Corps 75 (7.0%) 59 (7.3%) 
 
Navy 248 (23.2%) 164 (20.2%) 
 
Other 4 (0.4%) 2 (0.2%) 
 
Geographic region [n (%)] 
   
West 116 (10.9%) 73 (9.0%) 0.0038 
Central 141 (13.2%) 151 (18.6%) 
 
Northeast 378 (35.4%) 299 (36.8%) 
 
Southeast 366 (34.3%) 229 (28.2%) 
 
Alaska/Hawaii 40 (3.7%) 40 (4.9%) 
 
Non-US 27 (2.5%) 21 (2.6%) 
 
Rank of Sponsor [n (%)] 
   
Enlisted, Junior 77 (7.2%) 47 (5.8%) <0.0001 
Enlisted, Senior 804 (75.3%) 525 (64.6%) 
 
Warrant Officer 36 (3.4%) 23 (2.8%) 
 
Officer, Junior 39 (3.7%) 49 (6.0%) 
 
Officer, Senior 112 (10.5%) 169 (20.8%) 
 
Emergency Care During 6-Month Baseline 
   
Patients with ER Visits [n (%)] 168 (15.7%) 106 (13.0%) 0.1 
ER Days [mean (SD)] 0.23 (0.7) 0.16 (0.5) 0.0082 
Patients with Hospitalization [n (%)] 14 (1.3%) 4 (0.5%) 0.093 
Hospitalization Days [mean (SD)] 0.4 (5.9) 0.0 (0.5) 0.063 
Emergency Care at T1DM Presentation 
   
Admitted to ER [n (%)] 623 (58.3%) 504 (62.0%) 0.11 
Patients with Hospitalization [n (%)] 676 (63.3%) 566 (69.6%) 0.0041 
Hospitalization Days [mean (SD)] 2.4 (2.4) 2.5 (2.1) 0.44 
 Table 4 displays characteristics for patients who did not change treatment modality during follow 
compared to patients who initiated CSII and/or CGM. The index therapy refers to the mode of treatment 
being used three months after T1DM presentation. *We calculated statistical significance of continuous 
variables using a t-test and significance of binary and categorical variables using a chi square.  
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Table 5: Proportional Hazards Claims Analyses of Time to Initiation of CSII (n=1,953). 
Patient Characteristic 
Bivariate Analysis Multivariate Claims Model Final Claims Model 
HR (95% C.L.) P-value HR (95% C.L.) P-value HR (95% C.L.) P-value 
Previous CGM Use 2.46 (1.79,3.39) <.0001 2.40 (1.74, 3.31) <.0001 2.40 (1.74, 3.30) <.0001 
Female Gender 1.35 (1.18,1.55) <.0001 1.30 (1.13, 1.49) 0.0002 1.28 (1.12, 1.47) 0.0004 
Age on Index Day 0.93 (0.91,0.95) <.0001 0.94 (0.92, 0.96) <.0001 0.94 (0.92, 0.96) <.0001 
Patients with Index BMI Value 1.09 (0.94,1.27) 0.27    
 
    Index BMI Value 0.89 (0.86,0.92) <.0001    
 
Patients with Index HbA1c Value 0.93 (0.76,1.13) 0.46    
 
    Index HbA1c Value 1.05 (0.99, 1.12) 0.14    
 
Year of Diagnosis (p-value) 
 
0.78    
 
    2008 Ref.     
 
    2009 1.02 (0.84, 1.25) 0.82    
 
    2010 1.14 (0.92, 1.40) 0.24    
 
    2011 1.02 (0.82, 1.28) 0.84    
 
    2012 0.99 (0.76, 1.29) 0.94    
 
    2013 1.23 (0.75, 2.03) 0.42    
 












    Army 1.10 (0.92, 1.33) 0.30 1.10 (0.91, 1.34) 0.31  
 
    Marine Corps 1.13 (0.83, 1.53) 0.44 1.01 (0.74, 1.37) 0.96  
 
    Coast Guard 1.23 (0.77, 1.98) 0.39 1.05 (0.65, 1.70) 0.83  
 
    Air Force 1.37 (1.13, 1.67) 0.002 1.24 (1.01, 1.52) 0.04  
 
    Other 1.88 (0.60, 5.90) 0.28 1.14 (0.36, 3.62) 0.82  
 







    West Ref. 
 
Ref.  Ref.  
    Southeast 1.04 (0.80, 1.35) 0.78 1.02 (0.78, 1.33) 0.89 1.06 (0.82, 1.38) 0.66 
    Alaska/Hawaii 1.09 (0.74, 1.61) 0.67 0.90 (0.61, 1.34) 0.61 0.93 (0.63, 1.38) 0.72 
    Non-US 1.17 (0.74, 1.86) 0.49 0.96 (0.60, 1.53) 0.85 1.01 (0.64, 1.61) 0.96 
    Northeast 1.22 (0.95, 1.58) 0.12 1.17 (0.91, 1.51) 0.23 1.17 (0.91, 1.51) 0.23 
    Central 1.51 (1.14, 1.99) 0.004 1.39 (1.04, 1.85) 0.02 1.49 (1.13, 1.96) 0.005 







    Enlisted, Junior Ref.  Ref.  Ref.  
    Enlisted, Senior 0.97 (0.73, 1.30) 0.84 0.97 (0.72, 1.31) 0.83 0.99 (0.74, 1.32) 0.93 
    Warrant Officer 1.02 (0.63, 1.67) 0.92 1.09 (0.67, 1.79) 0.73 1.10 (0.67, 1.80) 0.70 
    Officer, Junior 1.46 (0.99, 2.16) 0.06 1.33 (0.89, 1.98) 0.16 1.38 (0.93, 2.04) 0.11 
    Officer, Senior 1.84 (1.34, 2.53) 0.0002 1.72 (1.25, 2.39) 0.001 1.81 (1.32, 2.49) 0.0002 
Emergency Care  During 6-
Month Baseline 
   
    Patients with ER Visits 0.86 (0.70, 1.05) 0.13     
    ER Days 0.86 (0.75, 0.99) 0.03 0.92 (0.80, 1.05) 0.22   
    Patients with Hospitalization 0.58 (0.24, 1.39) 0.22     
    Hospitalization Days  0.92 (0.83, 1.02) 0.11     
Emergency Care  at T1DM 
Presentation  
  
    Admitted to ER 1.08 (0.94, 1.24) 0.2778     
    Patients with Hospitalization 1.27 (1.10, 1.47) 0.0014 1.16 (1.00, 1.35) 0.0566   
    Hospitalization Days  1.02 (0.99, 1.05) 0.2078     
HR: Hazard Ratio  
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Table 6: Proportional Hazards Claims Analyses of Time to Initiation of CGM (n=1,953). 
Patient Characteristic 
Bivariate Analysis Multivariate Claims Model Final Claims Model 
HR (95% C.L.) 
P-
value 
HR (95% C.L.) 
P-
value 
HR (95% C.L.) 
P-
value 










Female Gender 1.34 (1.09, 1.65) 0.006 1.15 (0.93, 1.44) 0.20   
Age on Index Day 0.96 (0.93, 0.99) 0.008 0.99 (0.96, 1.03) 0.72   
Patients with Index BMI Value 0.96 (0.75, 1.23) 0.76     
    Index BMI Value 0.90 (0.86, 0.95) 0.0001     
Patients with Index HbA1c Value 0.68 (0.48, 0.97) 0.03 0.99 (0.96, 1.03) 0.32   
    Index HbA1c Value 1.04 (0.93, 1.16) 0.53 
  
  







    2008 Ref.  Ref.  Ref.  
    2009 1.18 (0.86, 1.61) 0.32 1.53 (1.10, 2.13) 0.01 1.51 (1.10, 2.08) 0.01 
    2010 1.37 (0.97, 1.94) 0.08 2.20 (1.52, 3.19) <.0001 2.23 (1.57, 3.18) <.0001 
    2011 1.77 (1.22, 2.58) 0.003 4.78 (3.21, 7.14) <.0001 4.73 (3.20, 6.99) <.0001 
    2012 2.80 (1.81, 4.32) <.0001 
10.42 (6.49, 
16.73) 
<.0001 10.15 (6.41, 16.09) <.0001 
    2013 2.36 (0.91, 6.10) 0.08 
13.20 (4.93, 
35.37) 
<.0001 13.74 (5.16, 36.57) <.0001 






    Navy Ref.  Ref.    
    Army 1.23 (0.91, 1.67) 0.18 1.09 (0.79, 1.50) 0.59   
    Marine Corps 1.91 (1.24, 2.94) 0.003 1.38 (0.89, 2.16) 0.15   
    Coast Guard 2.47 (1.35, 4.50) 0.003 1.74 (0.933.23) 0.08   
    Air Force 1.52 (1.11, 2.09) 0.01 1.06 (0.75, 1.50) 0.73   
    Other 
4.41 (1.08, 
18.06) 
0.04 3.69 (0.87, 15.60) 0.08   




0.22   
    West Ref.  Ref.    
    Southeast 1.03 (0.68, 1.56) 0.90 1.06 (0.68, 1.64) 0.80   
    Alaska/Hawaii 1.31 (0.73, 2.36) 0.37 1.01 (0.55, 1.85) 0.99   
    Non-US 0.67 (0.28, 1.62) 0.38 0.65 (0.26, 1.62) 0.36   
    Northeast 1.19 (0.79, 1.78) 0.41 1.08 (0.71, 1.65) 0.72   
    Central 1.90 (1.24, 2.91) 0.003 1.44 (0.91, 2.27) 0.12   




0.07   
    Enlisted, Junior Ref.  Ref.    
    Enlisted, Senior 1.06 (0.66, 1.72) 0.80 1.11 (0.67, 1.82) 0.69   
    Warrant Officer 1.56 (0.78, 3.13) 0.21 1.58 (0.78, 3.22) 0.21   
    Officer, Junior 1.47 (0.79, 2.75) 0.22 1.43 (0.75, 2.72) 0.28   
    Officer, Senior 1.79 (1.07, 2.99) 0.03 1.57 (0.92, 2.71) 0.10   
Emergency Care During 6-Month 
Baseline  
  
    Patients with ER Visits 0.79 (0.56, 1.10) 0.16     
    ER Days 0.86 (0.69, 1.08) 0.20     
    Patients with Hospitalization 0.98 (0.32, 3.06) 0.97     
    Hospitalization Days  0.97 (0.87, 1.07) 0.52     
Emergency Care at T1DM 
Presentation  
  
    Admitted to ER 1.07 (0.87, 1.33) 0.52     
    Patients with Hospitalization 1.15 (0.92, 1.44) 0.22     
    Hospitalization Days  1.02 (0.99, 1.05) 0.28     
HR: Hazard Ratio   
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HR (95% C.L.) 
P-
value 
HR (95% C.L.) 
P-
value 
Female Gender 1.07 (0.85,1.34) 0.56   
Age on Index Day 1.02 (0.99, 1.05) 0.28   
Patients with Index BMI Value 1.02 (0.79,1.33) 0.86   
    Index BMI Value 0.99 (0.94, 1.05) 0.80   
Patients with Index HbA1c Value 0.75 (0.52, 1.09) 0.13   
    Index HbA1c Value 1.04 (0.92, 1.17) 0.58   





    2008 Ref. 
 
Ref.  
    2009 1.25 (0.90, 1.75) 0.19 1.21 (0.86, 1.70) 0.27 
    2010 1.46 (1.01, 2.11) 0.04 1.34 (0.92, 1.94) 0.13 
    2011 2.39 (1.61, 3.55) <.0001 2.37 (1.59, 3.53) <.0001 
    2012 5.49 (3.45, 8.75) <.0001 5.51 (3.44, 8.81) <.0001 
    2013 5.03 (1.53, 16.58) 0.008 4.87 (1.47, 16.09) 0.009 





    Navy Ref.  Ref.  
    Army 1.22 (0.88, 1.69) 0.24 1.09 (0.77, 1.52) 0.64 
    Marine Corps 1.94 (1.22, 3.07) 0.005 1.89 (1.19, 3.00) 0.008 
    Coast Guard 2.44 (1.27, 4.68) 0.007 2.39 (1.24, 4.61) 0.009 
    Air Force 1.28 (0.91, 1.80) 0.16 1.15 (0.81, 1.65) 0.44 
    Other 4.10 (1.00, 16.85) 0.05 4.44 (1.06, 18.65) 0.041 









    Southeast 0.89 (0.57, 1.39) 0.61 0.98 (0.62, 1.55) 0.94 
    Alaska/Hawaii 1.05 (0.56, 1.95) 0.89 1.14 (0.61, 2.15) 0.68 
    Non-US 0.58 (0.24, 1.41) 0.23 0.66 (0.27, 1.63) 0.37 
    Northeast 1.00 (0.65, 1.54) 0.99 1.12 (0.72, 1.72) 0.62 
    Central 1.42 (0.91, 2.22) 0.13 1.58 (0.99, 2.52) 0.06 




    Enlisted, Junior Ref.    
    Enlisted, Senior 1.04 (0.62, 1.73) 0.88   
    Warrant Officer 1.43 (0.68, 3.02) 0.35   
    Officer, Junior 1.22 (0.64, 2.33) 0.55   
    Officer, Senior 1.21 (0.70, 2.09) 0.49   
Emergency Care During 6-Month Baseline 
 
 
    Patients with ER Visits 0.98 (0.70, 1.37) 0.90   
    ER Days 1.06 (0.83, 1.35) 0.65   
    Patients with Hospitalization 1.71 (0.55, 5.34) 0.35   
    Hospitalization Days  1.13 (0.95, 1.34) 0.16   
Emergency Care at T1DM Presentation 
 
 
    Admitted to ER 1.03 (0.82, 1.30) 0.80   
    Patients with Hospitalization 1.03 (0.81, 1.32) 0.79   
    Hospitalization Days  1.01 (0.99, 1.04) 0.35   
HR: Hazard Ratio   
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Table 8: Cox Proportional Hazards EMR Analyses of Time to Initiation of CSII (n=521). 
Patient Characteristic 
Multivariate EMR Model Final EMR Model 
HR (95% C.L.) 
P-
value 
HR (95% C.L.) 
P-
value 
Previous CGM Use 1.85 (0.67,5.08) 0.24     
Female Gender 1.23 (0.94, 1.62) 0.13     
Age on Index Day 0.96 (0.91, 1.00) 0.05     
Patients with Index BMI Value         
    Index BMI Value 0.91 (0.88, 0.95) <.0001 0.89 (0.86, 0.92) <.0001 
Patients with Index HbA1c Value 1.85 (0.67, 5.08) 0.24     
    Index HbA1c Value         
Year of Diagnosis (p-value)     
    2008         
    2009         
    2010         
    2011         
    2012         
    2013         
Military branch (p-value)  0.18   
    Navy Ref.      
    Army 0.81 (0.56, 1.18) 0.28     
    Marine Corps 0.57 (0.29, 1.10) 0.09     
    Coast Guard 0.21 (0.03, 1.58) 0.13     
    Air Force 1.07 (0.73, 1.56) 0.75     
    Other 0.86 (0.19, 3.84) 0.84     
Geographic region (p-value)  0.03  0.01 
    West Ref.  Ref.  
    Southeast 0.76 (0.46, 1.25) 0.28 0.88 (0.55, 1.41) 0.59 
    Alaska/Hawaii 0.75 (0.40, 1.41) 0.37 0.81 (0.44, 1.50) 0.51 
    Non-US 0.67 (0.27, 1.66) 0.39 0.73 (0.30, 1.79) 0.49 
    Northeast 0.76 (0.47, 1.23) 0.26 0.84 (0.53, 1.33) 0.45 
    Central 1.41 (0.83, 2.39) 0.21 1.62 (0.99, 2.65) 0.05 





    Enlisted, Junior Ref.  Ref.  
    Enlisted, Senior 1.10 (0.44, 2.74) 0.84 1.23 (0.50, 3.02) 0.65 
    Warrant Officer 1.66 (0.56, 4.92) 0.36 1.66 (0.57, 4.89) 0.35 
    Officer, Junior 2.01 (0.73, 5.57) 0.18 2.16 (0.79, 5.86) 0.13 
    Officer, Senior 2.13 (0.84, 5.43) 0.11 2.24 (0.90, 5.60) 0.08 
Emergency Care During 6-Month Baseline 
  
    Patients with ER Visits     
    
    ER Days 0.93 (0.71, 1.22) 0.60 
    
    Patients with Hospitalization     
    
    Hospitalization Days      
    
Emergency Care at T1DM Presentation 
  
    Admitted to ER 
        
    Patients with Hospitalization 1.13 (0.81,1.56) 0.47 
    
    Hospitalization Days  
        




Table 9: Cox Proportional Hazards EMR Analyses of Time to Initiation of CGM 
(n=521). 
Patient Characteristic 
Multivariate EMR Model Final EMR Model 
HR (95% C.L.) P-value HR (95% C.L.) 
P-
value 
Previous CSII Use 25.61 (15.02, 43.66) <.0001 27.00 (16.47, 44.28) <.0001 
Female Gender 1.20 (0.75, 1.92) 0.46     
Age on Index Day 1.01 (0.92, 1.10) 0.85     
Patients with Index BMI Value         
    Index BMI Value 0.93 (0.87, 1.00) 0.05 0.94 (0.890.99) 0.03 
Patients with Index HbA1c Value 0.85 (0.51, 1.43) 0.55     
    Index HbA1c Value         
Year of Diagnosis (p-value)  <.0001  <.0001 
    2008 Ref.  Ref.  
    2009 2.37 (0.31, 18.00) 0.40 2.40 (0.32, 17.89) 0.39 
    2010 2.29 (0.29, 17.93) 0.43 3.08 (0.41, 23.33) 0.28 
    2011 7.29 (0.93, 56.97) 0.06 7.26 (0.95, 55.38) 0.06 
    2012 27.49 (3.38, 223.81) 0.002 27.46 (3.50, 215.47) 0.002 
    2013 14.34 (0.83, 248.01) 0.07 14.30 (0.85, 241.93) 0.07 
Military branch (p-value) Not Enough Data  Not Enough Data  
    Navy         
    Army         
    Marine Corps         
    Coast Guard         
    Air Force         
    Other         
Geographic region (p-value)  0.65   
    West Ref.      
    Southeast 0.91 (0.40, 2.06) 0.82     
    Alaska/Hawaii 0.68 (0.25, 1.85) 0.45     
    Non-US 0.31 (0.04, 2.51) 0.27     
    Northeast 0.86 (0.38, 1.95) 0.72     
    Central 1.27 (0.57, 2.82) 0.56     
Rank of Sponsor (p-value)  0.17   
    Enlisted, Junior Ref.      
    Enlisted, Senior 0.36 (0.12, 1.10) 0.07     
    Warrant Officer 0.38 (0.08, 1.89) 0.24     
    Officer, Junior 0.58 (0.16, 2.06) 0.40     
    Officer, Senior 0.63 (0.20, 1.99) 0.43     
Emergency Care During 6-Month 
Baseline 
  
    Patients with ER Visits         
    ER Days         
    Patients with Hospitalization         
    Hospitalization Days          
Emergency Care at T1DM 
Presentation 
  
    Admitted to ER         
    Patients with Hospitalization         









Figure 2: Study population average hemoglobin A1c by year of follow-up (n=1,953). 
 
 
Figure 2 displays a Lowess plot of the study population average hemoglobin A1c during follow-up (years). 
The effect of the “honeymoon period” is demonstrated by the characteristic improvement in glycemic 
control 3 months after presentation followed by a steady increase in hemoglobin A1c until approximately 
one year after diagnosis.   
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Figure 3: Kaplan Meier plot of time to CSII initiation (n=1,953). 
 
Figure 3 displays a Kaplan Meier plot of the cumulative proportion of patients initiating continuous 




Figure 4: Kaplan Meier plot of time to CGM initiation (n=1,953). 
 
Figure 4 displays a Kaplan Meier plot of the cumulative proportion of patients initiating continuous glucose 




Figure 5: Kaplan Meier plot of time CSII initiation by gender (n=1,953). 
 
Figure 5 displays a Kaplan Meier plot of the cumulative proportion of patients initiating continuous 
subcutaneous insulin infusion (CSII) by gender and the risk set at each year during follow-up. We 
calculated statistical significance of the difference in the proportion of males and females initiating CSII 




Figure 6: Kaplan Meier plot of time to CGM initiation by gender (n=1,953). 
 
Figure 6 displays a Kaplan Meier plot of the cumulative proportion of patients initiating continuous glucose 
monitoring (CGM) by gender and the risk set at each year during follow-up. We calculated statistical 





Figure 7: Kaplan Meier plot of time from CSII to CGM initiation by gender (n=790). 
 
Figure 7 displays a Kaplan Meier plot of the cumulative proportion of patients initiating continuous glucose 
monitoring (CGM) by gender and the risk set at each year during follow-up. All patients included in this 
analysis had previously initiated continuous subcutaneous insulin infusion (CSII). We calculated statistical 





Figure 8: Kaplan Meier plot of time to CSII initiation by year of diagnosis (n=1,953). 
 
Figure 8 displays a Kaplan Meier plot of the cumulative proportion of patients initiating continuous 
subcutaneous insulin infusion (CSII) by calendar year of T1DM presentation and the risk set at each year 
during follow-up. We calculated statistical significance of the difference in the proportion of patients 





Figure 9: Kaplan Meier plot of time to CGM initiation by year of diagnosis (n=1,953). 
 
Figure 9 displays a Kaplan Meier plot of the cumulative proportion of patients initiating continuous glucose 
monitoring (CGM) by calendar year of T1DM presentation and the risk set at each year during follow-up. 
We calculated statistical significance of the difference in the proportion of patients initiating CGM during 




Table A1: Patient Attrition. 
Inclusion/Exclusion Criteria Patients Remaining 
Patients 
Excluded 
    Patient has a DM Dx 13,977 (100.0%) 
 
    Patient has sufficient DM Dx/med criteria 9,610 (68.8%) 4,367 (31.2%) 
    Patient was less than 19 years old at the time of first diagnosis 9,608 (68.7%) 2 (0.0%) 
    Patient has sufficient baseline (182 days) enrollment 4,274 (30.6%) 5,334 (38.2%) 
    Patient has sufficient follow-up (122 days) enrollment 4,122 (29.5%) 152 (1.1%) 
    Patient not excluded for pregnancy 4,053 (29.0%) 69 (0.5%) 
    Patient not excluded for condition Dx 3,757 (26.9%) 296 (2.1%) 
    Patient has algorithm defined T1DM 1,953 (14.0%) 1,804 (12.9%) 
Appendix Table 1 displays the number of patients excluded and the number of patient remaining after each 




















Gender [n (%)] 
     
    Female 882 (45.2%) 840 (44.7%) 2 (66.7%) 37 (59.7%) 3 (42.9%) 
    Male 1071 (54.8%) 1041 (55.3%) 1 (33.3%) 25 (40.3%) 4 (57.1%) 
Age on Index Day [mean (SD)] 12.4 (3.3) 12.4 (3.3) 10.3 (1.5) 12.7 (3.8) 16.3 (3.3) 
Patients with Index BMI Value [n (%)] 521 (26.7%) 505 (26.8%) 0 (0.0%) 12 (19.4%) 4 (57.1%) 
    BMI Value [mean (SD)] 20.1 (5.7) 20.2 (5.8) NA 18.3 (3.4) 18.4 (4.1) 
Patients with Index HbA1c Value [n (%)] 289 (14.8%) 283 (15.0%) 0 (0.0%) 6 (9.7%) 0 (0.0%) 
    HbA1c Value [mean (SD)] 11.6 (2.9) 11.6 (2.9) NA 12.9 (2.8) NA 
Year of Diagnosis [n (%)] 
     
    2008 316 (16.2%) 304 (16.2%) 1 (33.3%) 10 (16.1%) 1 (14.3%) 
    2009 421 (21.6%) 406 (21.6%) 0 (0.0%) 14 (22.6%) 1 (14.3%) 
    2010 376 (19.3%) 356 (18.9%) 0 (0.0%) 19 (30.6%) 1 (14.3%) 
    2011 381 (19.5%) 372 (19.8%) 0 (0.0%) 8 (12.9%) 1 (14.3%) 
    2012 334 (17.1%) 322 (17.1%) 2 (66.7%) 7 (11.3%) 3 (42.9%) 
    2013 125 (6.4%) 121 (6.4%) 0 (0.0%) 4 (6.5%) 0 (0.0%) 
Military branch [n (%)] 
     
    Army 853 (43.7%) 821 (43.6%) 1 (33.3%) 29 (46.8%) 2 (28.6%) 
    Coast Guard 41 (2.1%) 39 (2.1%) 0 (0.0%) 1 (1.6%) 1 (14.3%) 
    Air Force 496 (25.4%) 469 (24.9%) 2 (66.7%) 23 (37.1%) 2 (28.6%) 
    Marine Corps 135 (6.9%) 134 (7.1%) 0 (0.0%) 1 (1.6%) 0 (0.0%) 
    Navy 421 (21.6%) 412 (21.9%) 0 (0.0%) 8 (12.9%) 1 (14.3%) 
    Other 7 (0.4%) 6 (0.3%) 0 (0.0%) 0 (0.0%) 1 (14.3%) 
Geographic region [n (%)] 
     
    West 193 (9.9%) 189 (10.0%) 1 (33.3%) 1 (1.6%) 2 (28.6%) 
    Central 307 (15.7%) 292 (15.5%) 1 (33.3%) 13 (21.0%) 1 (14.3%) 
    Northeast 701 (35.9%) 677 (36.0%) 1 (33.3%) 23 (37.1%) 0 (0.0%) 
    Southeast 621 (31.8%) 595 (31.6%) 0 (0.0%) 22 (35.5%) 4 (57.1%) 
    Alaska/Hawaii 80 (4.1%) 80 (4.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
    Non-US 51 (2.6%) 48 (2.6%) 0 (0.0%) 3 (4.8%) 0 (0.0%) 
Rank of Sponsor [n (%)] 
     
    Enlisted, Junior 128 (6.6%) 124 (6.6%) 0 (0.0%) 4 (6.5%) 0 (0.0%) 
    Enlisted, Senior 1373 (70.3%) 1329 (70.7%) 3 (100.0%) 37 (59.7%) 4 (57.1%) 
    Warrant Officer 62 (3.2%) 59 (3.1%) 0 (0.0%) 2 (3.2%) 1 (14.3%) 
    Officer, Junior 91 (4.7%) 88 (4.7%) 0 (0.0%) 3 (4.8%) 0 (0.0%) 
    Officer, Senior 299 (15.3%) 281 (14.9%) 0 (0.0%) 16 (25.8%) 2 (28.6%) 
Emergency Care During 6-Month Baseline 
     
    Patients with ER Visits [n (%)] 277 (14.2%) 274 (14.6%) 1 (33.3%) 2 (3.2%) 0 (0.0%) 
    ER Days [mean (SD)] 0.2 (0.6) 0.2 (0.6) 1.0 (1.7) 0.0 (0.2) 0.0 (0.0) 
    Patients with Hospitalization [n (%)] 20 (1.0%) 18 (1.0%) 1 (33.3%) 1 (1.6%) 0 (0.0%) 
    Hospitalization Days [mean (SD)] 0.2 (4.4) 0.2 (4.5) 4.3 (7.5) 0.0 (0.4) 0.0 (0.0) 
Emergency Care at T1DM Presentation 
     
    Admitted to ER [n (%)] 1156 (59.2%) 1127 (59.9%) 1 (33.3%) 22 (35.5%) 6 (85.7%) 
    Patients with Hospitalization [n (%)] 1276 (65.3%) 1242 (66.0%) 2 (66.7%) 27 (43.5%) 5 (71.4%) 
    Hospitalization Days [mean (SD)] 2.5 (2.6) 2.5 (2.3) 2.0 (1.7) 2.3 (7.7) 2.1 (1.6) 
Appendix Table 2 displays patient characteristics for all patients and by index treatment group. The index 
therapy refers to the mode of insulin delivery being used three months after T1DM presentation.   
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CHAPTER 3: MANUSCRIPT 2 – GLYCEMIC CONTROL 
Abstract 
Purpose: The purpose of this study was to estimate the effects of initiating 
continuous subcutaneous insulin infusion (CSII) and/or a continuous glucose monitor 
(CGM) on hemoglobin A1c in an observational cohort of pediatric patients with type 1 
diabetes mellitus (T1DM). 
Methods: This study was performed using data extracted from the US Department 
of Defense (DOD) Military Health Systems (MHS) database between October 2007 and 
September 2013. Exploratory analyses were performed to develop an algorithm designed 
to identify diabetic patients and differentiate between type 1 and type 2 diabetes. We 
created a mixed effects model to estimate the effects of switching insulin delivery method 
from multiple daily injections (MDI) to continuous subcutaneous insulin infusion (CSII) 
and/or augmenting treatment with a continuous glucose monitor (CGM) on hemoglobin 
A1c. 
Results: We identified 1,318 pediatric patients with T1DM. We observed 174 
treatment switches and 159 augments, including 24 occurrences where a switch and 
augment occurred in the same time period. Changes in hemoglobin A1c after a treatment 
change depended on the initial hemoglobin A1c. We found patients with an initial A1c of 
6% did not experience improved glycemic control from a treatment change. However, a 
patient with an initial A1c of 9% would experience a reduction of 0.55% (p<0.0001) from 
a switch and 0.30% (p=0.002) from an augment, and a patient with a hemoglobin A1c of 
12% would experience a reduction of 1.13% (p<0.0001) from a switch and 0.51% 
(p=0.007) from an augment. 
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Conclusion: Many patients in our cohort demonstrated clinically meaningful 




Tight glycemic control is required to reduce the risk of complications from type 1 
diabetes mellitus (T1DM). Poor glycemic control in adolescence is associated with 
impaired cognitive function in adulthood.
1,2,3
 Repeated episodes of severe hypoglycemia 
(SH) can lead to seizures, cardiovascular disease, and cognitive decline.
4
 Long term 









, and kidney disease.
9
 An absolute reduction in 
hemoglobin A1c of 0.5% is considered to be clinically meaningful because this level of 
increased glycemic control results in significant reductions in chronic microvascular 
complications such as nephropathy and retinopathy.
10,11,12,13
 
Continuous subcutaneous insulin infusion (CSII), also known as an insulin pump, 
more closely imitates the body’s natural metabolic processes compared to multiple daily 
injections (MDI). A continuous glucose monitor (CGM) is a device that provides a 
glucose reading every few minutes so that patients may more easily recognize patterns 
and trends over time. In theory, these treatments should improve a patient’s glycemic 
control. However, clinical trials measuring the effects of CSII and/or CGM usage 
compared to conventional therapy, which consists of MDI and self-monitoring of blood 
glucose (SMBG) through finger sticks, on glycemic control have demonstrated mixed 
results. A recent systematic review comparing MDI with CSII found no statistically 
significant difference in hemoglobin A1c levels in children, though adults’ hemoglobin 
A1c levels were on average 0.3% lower with CSII.
14
 Clinical trials of CGM in children 
have generally not demonstrated clinically meaningful differences in glycemic control 
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In clinical trials, treatment groups are assigned. However, treatment choices in the 
real world are non-random and motivated by many factors. Consequently changes in 
glycemic control after initiation of CSII or CGM observed by patients participating in 
clinical trials may be different than what patients experience in typical care setting. In 
this study, we aimed to estimate changes in hemoglobin A1c associated with a change in 
treatment (initiation of CSII and/or CGM) in an observational cohort of pediatric patients 




This study was performed using data extracted from the US Department of 
Defense (DOD) Military Health Systems (MHS) database. The DOD MHS serves active 
and past military personnel (known as the sponsor) and their dependents. The database 
includes both an electronic medical record (EMR) and a medical insurance claims 
component. All patients are included in the insurance claims data, and approximately one 
third have EMR data. Data collected includes: demographics, diagnostic codes, 
information on medical procedures, symptoms, vital signs, laboratory and radiology 
results, and pharmacy orders and claims. The crude data, prepared by Health Research Tx 
(HRTx), included all EMR encounters and insurance claims for patients with at least one 
International Classification of Diseases, Ninth Revision (ICD-9) diagnostic code 
indicating diabetes (250.XX) before their 19
th
 birthday. All personal identifiable 
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information was removed. At the time of extraction, data were available between October 
2007 and September 2013. 
Patients in the DOD MHS dataset during the study period meeting the following 
criteria were selected for this study: 
 At least one of the following: 
o One hospitalization with an ICD-9 diagnostic code for DM (250.XX) 
o Two DM diagnostic codes within one year 
o One diagnostic code for DM and one treatment for DM 
 Patient has algorithm defined type 1 diabetes 
 Age 18 years or younger at first diabetes diagnosis 
 A minimum of 16 months of enrollment after first DM diagnosis 
 A minimum of 2 hemoglobin A1c measurements occurring more than one year 
after first diabetes diagnosis date 
Previous studies,
 18,19
 as well as our own exploratory analyses, have shown that 
glycemic control varies drastically during the first year after type 1 diabetes diagnosis. 
Because we could not perfectly distinguish between incident and prevalent diabetes, we 
required a 12 month baseline period after the first indication of T1DM in the data, and no 
outcomes were measured until completion of the baseline period. Among patients 
meeting the eligibility criteria, the first day after the completion of the baseline period 
was considered the index day for the study. We also required at minimum of 4 months of 
follow-up. These requirements enabled us to create cohort with established, and thus, 
more stable diabetes and with enough follow-up to measure study outcomes (time for two 
or more hemoglobin A1c measurements). 
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Exclusion criteria were chosen to reduce the number of patients with gestational or 
other secondary (non-type 1 or 2) diabetes. Patients also needed to be at risk of changing 
treatment during follow-up. Patients meeting the following criteria were excluded from 
the study: 
 Patients becoming pregnant less than four months after index date were excluded. 
(Patients becoming pregnant greater than four months after index were censored 
at the pregnancy date.)  
 Patients with an ICD-9 code indicating any of the following: secondary diabetes 
(249.x), other endocrine dysfunction (251.8), adrenal cortical steroids causing 
adverse effects in therapeutic use (E932.0), adenocarcinomas (151.0), lupus 
erythematosus (710.0, 695.4), cystic fibrosis (277.0, 277.0X), hemochromatosis 
(275.0), acromegaly (253.0), Cushing’s syndrome (255.0),  own syndrome 
(758.0), Klinefelter syndrome (758.7), Turner syndrome (758.6), Huntington 
chorea (333.4), or Laurence-Moon-Biedl syndrome (759.89). 
 Patients using both CSII and CGM within one year of first diagnosis 
 
Diabetes Type Algorithm 
Previous studies have shown that T1DM diagnostic codes and insulin 
prescriptions can be used to identify pediatric T1DM patients in claims and EMR data 
with high specificity.
20,21,22,23
 Using this information, we performed exploratory data 
analyses to develop an algorithm to differentiate between type 1 and type 2 diabetes in 
the MHS data. To achieve this, we created a cohort of patients with only type 1 (250.x1or 
250.x3) or with only type 2 (250.x2) ICD-9 diagnostic codes. The characteristics of these 
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patients were used to differentiate between diabetes types for those patients where 
diagnostic codes were of mixed type or only included unspecified diabetes (250.00). The 
final differentiating algorithm was: at least two T1DM medication orders on separate 
days and (at least one T1DM diagnostic code or zero T2DM diagnostic codes).  
 
Mode of Diabetic Treatment  
Patients identified as T1DM were described by index treatment group. The index 
treatment was defined as the treatment method the patient was using on the index day 
(after completion of the 12 month baseline). Patients were described in the following 
three groups: 
 MDI and SMBG (conventional therapy) 
 MDI and CGM 
 CSII and SMBG 
For the purposes of this study, a treatment “switch” was defined as a change in insulin 
delivery method, from multiple daily injections to CSII. An “augment” was defined as 
initiation of CGM, as CGM is meant to be used in addition to SMBG. Once a patient 
initiated CSII and/or CGM, they were considered to be using the therapy until the end of 
follow-up. Patients using both CSII and CGM during the baseline period were excluded 
from the study, as they were not at risk of a switch or augment during follow-up. 
 
Statistical Analyses 
We calculated means and frequency distributions of patient characteristics to 
describe the study population as a whole and by treatment group at study entry. We 
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characterized patients at study entry in terms of age, gender, BMI at index, hemoglobin 
A1c at index, geographic region, and military branch and rank of sponsor and created 
Lowess plots of hemoglobin A1c centered on data of switch/augment to visualize 
changes in A1c occurring around the time of treatment change. 
We created a linear multilevel mixed effects model to estimate the fixed effect of 
a treatment switch or augment on the subsequent hemoglobin A1c allowing for random 
intercepts within patients. Patient follow-up was divided into periods beginning and 
ending with a hemoglobin A1c measurement so that we could measure the difference in 
hemoglobin A1c between the start and end of a given period. Period duration, 
hemoglobin A1c before the treatment change, and significantly associated characteristics 
were adjusted for in the multivariate model. Indicator variables were created to indicate 
during which periods the patient chose to switch and/or augment treatment. Because 
hemoglobin A1c is the measure of average blood glucose over the past two to three 
months, we built in 30 day lag to allow some time for hemoglobin A1c to change after a 
switch/augment. Treatment indicators were also created to indicate during which periods 
patients used CSII and/or CGM, subsequent to a switch and/or augment. If, for example, 
a patient switched treatment during a given time period, for that period, the indicator for 
switch would equal one and the indicator for CSII would equal zero. For all subsequent 
time periods, the indicator for switch would revert to zero, but the indicator for CSII use 
would equal one. The mixed model was specifically designed to measure the difference 
between change in hemoglobin A1c in periods with a switch and/or augment and change 
in hemoglobin A1c in periods with no treatment change. Thus, we could measure the 
short-term effects of a treatment switch and/or augment. Using separate indicators for 
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switch/augment and continued CSII/CGM use allowed us to separately measure short-
term as well as long-term changes in hemoglobin A1c in response to treatment. 
We hypothesized there may be an interaction between a treatment switch and 
treatment augment, where patients changing from conventional therapy simultaneously to 
CSII and CGM may experience a benefit differing from the sum of each individual 
therapy. We also hypothesized that changes in hemoglobin A1c after initiation of CSII 
and/or CGM may depend on the hemoglobin A1c value preceding the treatment change 
so that patients with a higher initial A1c may experience greater reductions after a switch 
and/or augment. Interaction terms for these items were added to the model and tested for 
significance. We created three statistical models to estimate the effect of a treatment 
change on hemoglobin A1c: a minimal model which included only treatment indicators 
and hemoglobin A1c, a full model with all variables significantly associated in bivariate 
analyses, and a final reduced model created by including all significant covariates using 
backwards selection.  
All statistical analyses were performed on the HRTx Citrix server using SAS 
version 9.3. Summaries from regression analyses of primary outcomes are displayed in 




Our study population consisted of 1,318 individuals, including 683 males and 635 
females. The average age on the index day was 13.6 years old. The average first 
hemoglobin A1c recording was 9.1% (median: 8.7%) and the average first BMI 
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measurement was 23.9 kg/m
2
. Multiple daily injections with self-monitoring of blood 
glucose (conventional therapy) was the most common (n=810; 61.5%) index therapy, 
followed by CSII with SMBG (n=502; 38.1%), and MDI with CGM (n=6; 0.5%). At 
study onset, a lower proportion of patients using CSII had a low military rank of sponsor 
(3.8% “Enlisted, Junior” vs. 6.0% for M I) and higher proportion had a high sponsor 
rank (27.9% “Officer, Senior” vs. 13.0% for M I) compared to patients using MDI 
(p<0.0001). Patient characteristics by index treatment group are displayed in Table 1. 
Patient selection and treatment patterns are displayed in Figure 1. 
 
Crude Effects of Treatment Change on Hemoglobin A1c 
Patients recorded 8,371 hemoglobin A1c measurements during follow-up, 
resulting in 7,053 time periods eligible for analysis. The mean period length was 170 
days with a median of 120 days. There were 174 treatment switches and 159 augments, 
including 24 occurrences where a switch and augment occurred in the same time period. 
The average hemoglobin A1c during follow-up was 9.10% (median: 8.70%). The mean 
hemoglobin A1c before a treatment switch was 9.05% and the mean A1c before an 
augment was 8.78%. The average hemoglobin A1c preceding a period where a patient 
both switched and augmented therapy was 9.23%. On average, patients with no treatment 
change during a given period experienced a small (0.02%) increase in hemoglobin A1c; 
however, patients with a treatment switch (-0.53%), augment (-0.20%), or both (-0.77%) 
experienced a reduction. Lowess plots of hemoglobin A1c centered on switch (Figure 2) 




Mixed Models Measuring the Effects of Treatment Change on Hemoglobin A1c 
The interaction between a treatment switch and augment was not statistically 
significant (p=0.93) and was not included in our final mixed model. However, terms for 
the interaction between the hemoglobin A1c measurement preceding a switch (p<0.0001) 
or an augment (p=0.17) were included in our multivariate models. In our final 
multivariate model, rank of sponsor (p<0.0001) and period duration (p<0.0001) were 
significantly associated with a change in hemoglobin A1c, but age (p=0.61), gender 
(p=0.83), military branch of sponsor (p=0.74), and geographic region (p=0.50) were not. 
We estimated that patients experienced a 0.57% (p<0.0001) average reduction in the next 
hemoglobin A1c for a switch and a 0.31% (p=0.0016) average reduction for an augment. 
For every 1% increase in hemoglobin A1c, patients experienced a 0.19% greater 
reduction in A1c from a switch and a 0.07% greater reduction from an augment. We 
predicted that patients with an initial hemoglobin A1c of 6% would experience no 
statistically significant changes in A1c after a treatment change. However, a patient with 
an initial A1c of 9% would experience a reduction of 0.55% from a switch and 0.30% 
from an augment, and a patient with a hemoglobin A1c of 12% would experience a 
reduction of 1.13% from a switch and 0.51% from an augment. Indicators for continued 
use of CSII (p=0.16) and CGM (p=0.22) were not statistically significant. Results from 
mixed effects models are displayed in Table 2 and estimated effects of a treatment change 







Summary of Main Findings 
We found changes in hemoglobin A1c after a treatment change depended on the 
initial hemoglobin A1c. We estimated that patients with an initial A1c of 6% did not 
experience improved glycemic control from a treatment change, but for every 1% 
increase in initial hemoglobin A1c, patients experienced a 0.19% (p<0.0001) greater 
reduction in A1c from a switch and a 0.07% (p=0.17) greater reduction from an augment. 
There was no interaction (p=0.93) between a treatment switch and augment on the effect 
of hemoglobin A1c, suggesting the benefits of each treatment are additive in those 
patients who use both. 
 
Effect of Treatment Change on Hemoglobin A1c 
Early evidence, from the 1980’s and1990’s, of CSII demonstrated improvements 
in hemoglobin A1c compared to multiple daily injections.
24
 However, with the 
development of improved short- and long-acting insulin analogs, the benefits in glycemic 
control of CSII over MDI have become less distinct. While some studies have shown no 
benefit from CSII,
25,26,27
 others have shown modest improvements.
28,29
 Meta analyses of 
clinical trials on the benefits of CSII on hemoglobin A1c have found reductions on the 
order 0.3% or less compared to MDI.
30,31,32
 Furthermore, very few efficacy studies have 
focused on pediatric patients.
33
  
In our study, we observed a reduction in hemoglobin A1c after initiation of CSII 
that was, on average, clinically meaningful (greater than 0.5%) among pediatric T1DM 
patients. It is important to note that our study was not designed to measure the treatment 
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effects of CSII as is done in clinical trials. Instead, we estimated the average change in 
hemoglobin A1c after initiation of CSII compared to patients without a treatment change. 
Our study observed greater reductions in hemoglobin A1c after initiation of CSII than has 
been demonstrated by randomized trials. The effects we observed would have been the 
sum of the average treatment effect and other influences, such as patient motivation. 
A 2012 meta-analysis of clinical trials of CGM use in pediatric populations found 
an average improvement in hemoglobin A1c of approximately 0.3%.
34
 Trials have not 
demonstrated reductions in severe hypoglycemic events,
35
 though they have 
demonstrated reduced time spent in hypoglycemia (blood glucose < 70 mg/dL).
36
 Our 
analyses estimated similar reductions in hemoglobin A1c after initiation of CGM as those 
estimated by clinical trials. We also observed, as have others,
37
 that a higher hemoglobin 
A1c at baseline resulted in a greater reduction after a treatment change. Improvements in 
hemoglobin A1c after initiation of CGM were more modest compared to CSII. That 
continuous access to glucose levels does not result in greater improvements in glycemic 
control highlights the difficulty of maintaining glycemic homeostasis manually. 
We hypothesized there may be an interaction between treatment switch and 
augment, where patients who chose both treatments may experience an extra benefit. 
However, our test of statistical interaction was not significant, suggesting the glycemic 
benefits of CSII and CGM use were additive. This means, on average, a patient in our 
cohort using conventional therapy with a hemoglobin A1c approximately 9%, would 
experience a 0.55% reduction from initiating CSII, a 0.30% reduction from initiating 
CGM, or a 0.85% reduction should they do both.  
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We hypothesized a priori that patients with higher initial hemoglobin A1c levels 
would experience a greater reduction in A1c after a change in treatment. We found this to 
be true; though, more so for a switch than for an augment. Even though the interaction 
between initial hemoglobin A1c and augment was not statistically significant, we decided 
to leave this interaction in the model for two reasons. First, we hypothesized a priori that 
this interaction was important. Second, the lack of significance is likely due to low power 
rather than the absence of any real effect. We estimated, for example, that patients with 
an initial hemoglobin A1c of 6%, would experience virtually no effects from a treatment 
change. However, patients with an initial hemoglobin A1c of 9% and 12% would 
experience average reductions in hemoglobin A1c that were clinically meaningful from a 
treatment switch or augment, respectively. 
It is also of note that the average hemoglobin A1c was lower preceding an 
augment (8.78%) compared to measurements taken before a switch (9.05%). Evidence 
suggests improvements in glycemic control after initiation of CSII are likely 
sustained.
38,39
 Because patients in our cohort predominately initiated CSII before CGM, it 
is intuitive that patients initiating CGM, many of whom have already experience an A1c 
reduction subsequent to initiating CSII, would on average have lower hemoglobin A1c 
levels compared to patients initiating CSII. Our study was not designed (or powered) to 
measure long-term trends in glycemic improvement. However, the indicators for 
continued CSII and CGM use after a treatment change were associated with very small 
changes in hemoglobin A1c and were not statistically significant. This suggests that the 
benefits of a treatment change are measurable by the next hemoglobin A1c reading and 
that there may be no increase, or attenuation, in benefit in the long run.  
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Strengths and Limitations  
We hypothesized a priori that regression to the mean could occur among patients 
with high hemoglobin A1c levels. This would be of concern if high hemoglobin A1c was 
a motivating factor for a treatment change because regression to the mean could cause an 
artifact treatment effect. By using hemoglobin A1c at the end of each period as our 
dependent variable and adjusting for A1c levels at the beginning of the period, we 
estimated the difference in the predicted hemoglobin A1c after a treatment change 
compared to the predicted hemoglobin A1c when there was no treatment change while 
adjusting for the initial hemoglobin A1c (as well as other covariates). Thus, effects from 
regression to the mean were built into the predicted hemoglobin A1c. We chose to 
analyze our data using a mixed model so that we could account for regression to the mean 
as well as variable duration time periods, correlated data from repeated measures, and 
patient-level differences in hemoglobin A1c over time in our analyses. 
This study was completed using EMR and insurance claims data, which has 
several strengths and limitations. Electronic data are readily available and are an efficient 
method for measuring outcomes for large cohorts of patients. Also, using claims data to 
describe treatment patterns of T1DM patients should capture nearly all insulin, CSII, and 
CGM related purchases as these treatments are expensive and unlikely to be paid for out 
of pocket.  
There was likely some misclassification of diabetes type. Identification of patients 
with T1DM was based on algorithms developed during exploratory data analyses. It is 
possible, however, that some T1DM patients were missed and some T2DM patients were 
wrongfully included. Omission of T1DM patients may have reduced statistical power and 
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could have resulted in selection bias. Our differentiating algorithm was designed to be 
specific (rather than sensitive), so we believe it is unlikely that many patients with T2DM 
were wrongfully classified as type 1. This may reduce generalizability if patients who 
were omitted would have experienced different effects from a treatment change. 
Another limitation of EMR/claims data is the lack of information on important 
confounders. For example, we were unable to adjust for sociodemographic indicators, 
including race and ethnicity, in our analyses because this information was missing for 
more than 99% of patients. However, evidence from the literature suggests that patient 
sociodemographics may not be a strong confounder for this analysis. By definition a 
confounder must be independently associated with an outcome and its exposure. Though 
race has been associated with higher hemoglobin A1c levels, (the outcome),
40
 
socioeconomic status may explain much of this effect.
41
 Studies have also shown that 
socioeconomic characteristics, such as higher education and income, are superior 
predictors of CSII and CGM use (the exposure).
42,43,44
 While we did not have household 
income or education data, we were able to use military rank of sponsor in our analysis, 
which we believed could be a socioeconomic indicator. We observed a strong 
relationship between increasing military rank of sponsor and increased likelihood of 
CSII/CGM use, which supports the hypothesis that sponsor rank may be a socioeconomic 
indicator. 
Confounding by indication is also a well-established source of bias in these types 
of studies.
45
 Patients who changed treatment were characteristically different than those 
who did not. Patients may differ in terms of demographics, overall health, economic 
security, access to healthcare, intelligence, motivation, and many other traits. Because 
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some of these characteristics cannot be measured and adjusted for in an observational 
study, treatment effects are not measured as they would be in a clinical trial setting. 
However, this was not a primary objective of this study. Where the purpose of a clinical 
trial is to measure effects attributable to the treatment, the purpose of this study was to 
measure the average effect experienced by patients who choose (or whose care givers 
choose) to change treatment after adjusting for important confounders. Thus, the effects 
we aimed to measured were the sum of the treatment effects from CSII/CGM and other 
factors associated with treatment choices that could not be measured. 
Body mass index (BMI) was not included in the analysis because it was not available for 
every patient. We performed a sensitivity analysis to determine if most recently measured 
BMI would have made a meaningful difference in our estimates. BMI was not 
statistically significantly associated with hemoglobin A1c (p=0.07), and had virtually no 
effect on our estimates (see Table 4). 
T1DM patients identified in this study may not be representative of the pediatric 
T1DM population in the United States. As the dependents of active and past military 
personnel, patients in this study are likely demographically different than the general US 
pediatric population and likely experience different levels of healthcare. However, 
removing our socioeconomic indicator, military rank of sponsor, had very little effect on 
any of our estimates. Therefore, we have no reason to believe that the treatment effects 







The purpose of this study was to estimate the benefits of a treatment change to 
continuous subcutaneous insulin infusion and/or continuous glucose monitoring on 
glycemic control in an observational cohort of pediatric patients with type 1 diabetes. We 
found that patients experienced a reduction in their next hemoglobin A1c after a change 
in treatment. This effect was greater among those patients with a higher initial 
hemoglobin A1c. Many patients in our cohort demonstrated clinically meaningful 
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Gender (n, %) 
    
    Female 635 (48.2%) 376 (46.4%) 2 (33.3%) 257 (51.2%) 
    Male 683 (51.8%) 434 (53.6%) 4 (66.7%) 245 (48.8%) 
Age [mean (SD)] 13.6 (3.6) 13.7 (3.7) 13.8 (4.4) 13.6 (3.4) 
Body Mass Index [mean (SD)] 23.9 (5.0) 24.0 (5.3) 22.6 (2.9) 23.9 (4.6) 
Hemoglobin A1c [mean (SD)] 9.1 (2.1) 9.3 (2.3) 9.4 (2.7) 8.8 (1.8) 
Military branch (n, %) 
    
    Army 498 (37.8%) 301 (37.2%) 3 (50.0%) 194 (38.6%) 
    Coast Guard 35 (2.7%) 26 (3.2%) 0 (0.0%) 9 (1.8%) 
    Air Force 368 (27.9%) 208 (25.7%) 2 (33.3%) 158 (31.5%) 
    Marine Corps 64 (4.9%) 39 (4.8%) 1 (16.7%) 24 (4.8%) 
    Navy 346 (26.3%) 233 (28.8%) 0 (0.0%) 113 (22.5%) 
    Other 7 (0.5%) 3 (0.4%) 0 (0.0%) 4 (0.8%) 
Geographic region (n, %) 
    
    West 215 (16.3%) 127 (15.7%) 0 (0.0%) 88 (17.5%) 
    Central 114 (8.6%) 67 (8.3%) 0 (0.0%) 47 (9.4%) 
    Northeast 542 (41.1%) 346 (42.7%) 2 (33.3%) 194 (38.6%) 
    Southeast 331 (25.1%) 183 (22.6%) 3 (50.0%) 145 (28.9%) 
    Alaska/Hawaii 65 (4.9%) 52 (6.4%) 0 (0.0%) 13 (2.6%) 
    Non-US 51 (3.9%) 35 (4.3%) 1 (16.7%) 15 (3.0%) 
Rank of Sponsor (n, %) 
    
    Enlisted, Junior 68 (5.2%) 49 (6.0%) 0 (0.0%) 19 (3.8%) 
    Enlisted, Senior 886 (67.2%) 590 (72.8%) 5 (83.3%) 291 (58.0%) 
    Warrant Officer 38 (2.9%) 19 (2.3%) 0 (0.0%) 19 (3.8%) 
    Officer, Junior 80 (6.1%) 47 (5.8%) 1 (16.7%) 32 (6.4%) 
    Officer, Senior 245 (18.6%) 105 (13.0%) 0 (0.0%) 140 (27.9%) 
    Other 1 (0.1%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 
Table 1 displays patient characteristics for all patients and by index treatment group. The index therapy 
refers to the mode of treatment being used on the first day after the 12-month baseline period.
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Table2: Mixed Models for Changes in HbA1c After Treatment Change (n=1,318). 
Effect 
Model 
Minimal* Full** Final*** 
Δ A1c % (95% C.L.) p-value Δ A1c % (95% C.L.) p-value Δ A1c % (95% C.L.) p-value 
Switch -0.55 (-0.72, -0.37) <0.0001 -0.56 (-0.75, -0.38) <0.0001 -0.57 (-0.75, -0.39) <.0001 
Augment -0.20 (-0.38, -0.01) 0.04 -0.30 (-0.50, -0.11) 0.002 -0.31 (-0.50, -0.12) 0.002 
Switch*A1c Interaction -0.19 (-0.28, -0.09 ) <0.0001 -0.19 (-0.28, -0.10) <0.0001 -0.19 (-0.28, -0.10) <0.0001 
Augment*A1c Interaction -0.06 (-0.16, 0.04) 0.25 -0.07 (-0.17, 0.03) 0.17 -0.07 (-0.17, 0.03) 0.17 
CSII N/A  0.09 (-0.03, 0.21) 0.14 0.09 (-0.03, 0.20) 0.16 
CGM N/A  -0.08 (-0.21, 0.05) 0.25 -0.08 (-0.21, 0.04) 0.22 
Table 2 displays the predicted change in hemoglobin A1c from initiation of CSII (switch) or CGM (augment) as well as the predicted effects of continued CSII and CGM 
use. 
* Linear multilevel mixed effects model adjusted for initial hemoglobin A1c. Full results are displayed in Appendix Table 2. 
** Linear multilevel mixed effects model adjusted for age, gender, military branch of sponsor, military rank of sponsor, geographic region, period length, and initial 
hemoglobin A1c. Full results are displayed in Appendix Table 3. 









Minimal* Full** Final*** 
Δ A1c % (95% C.L.) p-value Δ A1c % (95% C.L.) p-value Δ A1c % (95% C.L.) p-value 
Switch 
6 0.03 (-0.31, 0.36) 0.88 0.03 (-0.31, 0.36) 0.87 0.02 (-0.31, 0.35) 0.91 
7 -0.16 (-0.42, 0.10) 0.22 -0.16 (-0.42, 0.10) 0.22 -0.17 (-0.43, 0.09) 0.20 
8 -0.35 (-0.54, -0.15) 0.0007 -0.35 (-0.56, -0.15) 0.0007 -0.36 (-0.57, -0.16) 0.0005 
9 -0.53 (-0.71, -0.35) <0.0001 -0.54 (-0.73, -0.36) <0.0001 -0.55 (-0.73, -0.37) <0.0001 
10 -0.72 (-0.91, -0.52) <0.0001 -0.73 (-0.94, -0.53) <0.0001 -0.74 (-0.95, -0.54) <0.0001 
11 -0.90 (-1.16, -0.65) <0.0001 -0.93 (-1.18, -0.67) <0.0001 -0.94 (-1.19, -0.68) <0.0001 
12 -1.09 (-1.41, -0.76) <0.0001 -1.12 (-1.45, -0.79) <0.0001 -1.13 (-1.46, -0.80) <0.0001 
Augment 
6 -0.02 (-0.35, 0.31) 0.91 -0.09 (-0.42, 0.24) 0.59 -0.10 (-0.42, 0.23) 0.57 
7 -0.08 (-0.33, 0.18) 0.55 -0.16 (-0.41, 0.10) 0.22 -0.16 (-0.42, 0.09) 0.21 
8 -0.13 (-0.33, 0.06) 0.19 -0.23 (-0.43, -0.02) 0.03 -0.23 (-0.43, -0.03) 0.02 
9 -0.19 (-0.38, -0.01) 0.04 -0.30 (-0.49, -0.11) 0.002 -0.30 (-0.49, -0.11) 0.002 
10 -0.25 (-0.47, -0.03) 0.03 -0.37 (-0.59, -0.14) 0.001 -0.37 (-0.59, -0.15) 0.001 
11 -0.31 (-0.59, -0.02) 0.04 -0.43 (-0.72, -0.15) 0.003 -0.44 (-0.73, -0.15) 0.003 
12 -0.36 (-0.73, 0.004) 0.05 -0.50 (-0.87, -0.14) 0.007 -0.51 (-0.87, -0.14) 0.007 
Table 3 displays the predicted change in hemoglobin A1c from initiation of CSII (switch) or CGM (augment) by initial hemoglobin A1c from 6% to 12%. 
* Linear multilevel mixed effects model adjusted for initial hemoglobin A1c. Detailed statistical results are displayed in Appendix Table 2. 
** Linear multilevel mixed effects model adjusted for age, gender, military branch of sponsor, military rank of sponsor, geographic region, period length, and initial 
hemoglobin A1c. Detailed statistical results are displayed in Appendix Table 3. 




Table 4: Mixed Model with BMI for Changes in HbA1c After Treatment Change. 
Effect 
Reduced Model without BMI* Reduced Model with BMI** 
Δ A1c % (95% C.L.) p-value Δ A1c % (95% C.L.) p-value 
Switch -0.57 (-0.75, -0.39) <.0001 -0.58 (-0.76, -0.40) <.0001 
Augment -0.31 (-0.50, -0.12) 0.002 -0.31 (-0.50, -0.12) 0.002 
Switch*A1c Interaction -0.19 (-0.28, -0.10) <0.0001 -0.19 (-0.28, -0.10) <0.0001 
Augment*A1c Interaction -0.07 (-0.17, 0.03) 0.17 -0.07 (-0.17, 0.03) 0.16 
CSII 0.09 (-0.03, 0.20) 0.16 0.08 (-0.04, 0.20) 0.20 
CGM -0.08 (-0.21, 0.04) 0.22 -0.08 (-0.21, 0.05) 0.21 
Table 4 displays a comparison of the main analysis (n=1,318) and the sensitivity analysis (n=1,295) 
including patients with data for BMI. 
* Linear multilevel mixed effects model adjusted for military rank of sponsor, period length, and initial 
hemoglobin A1c. 
** Linear multilevel mixed effects model adjusted for BMI, military rank of sponsor, period length, and 









Figure 2: Lowess plot of hemoglobin A1c values centered around switch (n=174). 
 
Figure 2 displays a Lowess plot of the average hemoglobin A1c during follow-up (years) among patients 
who initiated continuous subcutaneous insulin infusion (CSII) with follow-up time centered on the date of 
CSII initiation.   
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Figure 3: Lowess plot of hemoglobin A1c values centered around augment (n=149). 
 
Figure 3 displays a Lowess plot of the average hemoglobin A1c during follow-up (years) among patients 












Patient has a DM Dx 13,977 (100.0%) 
 
Patient has sufficient DM Dx/med criteria 9,610 (68.8%) 4,367 (31.2%) 
Patient has algorithm defined T1DM 6,691 (47.9%) 2,919 (20.9%) 
Patient was less than 18 years old at the time of first diagnosis 6,690 (47.9%) 1 (0.0%) 
Patient has sufficient follow-up (16 months) enrollment 5,710 (40.9%) 980 (7.0%) 
Patient has at least 2 eligible A1c records 1,525 (10.9%) 4,185 (29.9%) 
Patient not excluded for pregnancy 1,505 (10.8%) 20 (0.1%) 
Patient not excluded for condition Dx 1,373 (9.8%) 132 (0.9%) 
Patient is at risk of switch or augment 1,318 (9.4%) 55 (0.4%) 
Appendix Table 1 displays the number of patients excluded and the number of patient remaining after each 







Table A2: Minimal Mixed Model – Solution for Fixed Effects (n=1,318). 
Effect Level Hemoglobin A1c % Standard Error t Value Pr > |t| 
Intercept 
 
5.1832 0.5671 9.14 <.0001 
Switch No -1.1356 0.4367 -2.6 0.0093 
Switch Yes 0 . . . 
Augment No -0.3248 0.4475 -0.73 0.4679 
Augment Yes 0 . . . 
Pre-A1c*Switch No 0.5374 0.04981 10.79 <.0001 
Pre-A1c*Switch Yes 0.3523 0.06206 5.68 <.0001 
Pre-A1c*Augment No 0.05728 0.04994 1.15 0.2514 
Pre-A1c*Augment Yes 0 . . . 
Pre-A1c Value 
 
0 . . . 
Differences of Least Squares Means 
Effect Δ A1c % Standard Error t Value Pr > |t| Lower C.L. Upper C.L. 
Switch -0.5485 0.08969 -6.12 <.0001 -0.7244 -0.3727 
Augment -0.1963 0.09498 -2.07 0.0388 -0.3826 -0.01014 
Appendix Table 2 displays statistical results from the minimal linear multilevel mixed effects model. The 
intercept for each patient was the sum of the fixed effect (shown above) and the patient-level random effect 
(not shown). Summary information from these data are also displayed in Table 2.  
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4.6651 0.6548 7.12 <.0001 
Switch No -1.1717 0.4351 -2.69 0.0071 
Switch Yes 0 . . . 
Augment No -0.3236 0.4458 -0.73 0.468 
Augment Yes 0 . . . 
Pre-A1c*Switch Int. No 0.5106 0.04958 10.3 <.0001 
Pre-A1c*Switch Int. Yes 0.32 0.06176 5.18 <.0001 
Pre-A1c*Augment Int. No 0.06894 0.04968 1.39 0.1653 
Pre-A1c*Augment Int. Yes 0 . . . 
CSII No -0.08977 0.06093 -1.47 0.1408 
CSII Yes 0 . . . 
CGM No 0.07599 0.06618 1.15 0.2509 
CGM Yes 0 . . . 
Age 
 
0.00304 0.00594 0.51 0.6091 
Gender Female 0.01022 0.04775 0.21 0.8306 
Gender Male 0 . . . 
Sponsor Air Force 0.3183 0.318 1 0.3169 
Sponsor Army 0.3707 0.3165 1.17 0.2416 
Sponsor Coast Guard 0.2672 0.3447 0.78 0.4383 
Sponsor Marine Corps 0.3621 0.3316 1.09 0.2749 
Sponsor Navy 0.3824 0.3164 1.21 0.2269 
Sponsor Other 0 . . . 
Region Alaska/Hawaii -0.1923 0.1263 -1.52 0.1279 
Region Central -0.06239 0.1091 -0.57 0.5673 
Region Non-US 0.00685 0.1393 0.05 0.9608 
Region Northeast 0.0325 0.06788 0.48 0.6321 
Region Southeast 0.01896 0.07961 0.24 0.8118 
Region West 0 . . . 
Military Rank of 
Sponsor 
Enlisted 0.2103 0.05343 3.94 <.0001 
Military Rank of 
Sponsor 
Officer 0 . . . 
Period Length 
 
0.00072 9.7E-05 7.39 <.0001 
Pre-A1c Value 
 
0 . . . 
Differences of Least Squares Means 
Effect Δ A1c % 
Standard 
Error 
t Value Pr > |t| Lower C.L. Upper C.L. 
Switch -0.563 0.09294 -6.06 <.0001 -0.7452 -0.3808 
Augment -0.3036 0.09781 -3.1 0.0019 -0.4954 -0.1119 
CSII 0.08977 0.06093 1.47 0.1408 -0.02969 0.2092 
CGM -0.076 0.06618 -1.15 0.2509 -0.2057 0.05374 
Appendix Table 3 displays statistical results from the full linear multilevel mixed effects model. The 
intercept for each patient was the sum of the fixed effect (shown above) and the patient-level random effect 
(not shown). Summary information from these data are also displayed in Table 2.  
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Pr > |t| 
Intercept 
 
4.9936 0.5743 8.69 <.0001 
Switch No -1.1671 0.4353 -2.68 0.0074 
Switch Yes 0 . . . 
Augment No -0.3164 0.4457 -0.71 0.4779 
Augment Yes 0 . . . 
Pre-A1c*Switch Int. No 0.5181 0.04957 10.45 <.0001 
Pre-A1c*Switch Int. Yes 0.327 0.06176 5.29 <.0001 
Pre-A1c*Augment Int. No 0.06858 0.04968 1.38 0.1675 
Pre-A1c*Augment Int. Yes 0 . . . 
CSII No -0.0857 0.06038 -1.42 0.1558 
CSII Yes 0 . . . 
CGM No 0.07996 0.06493 1.23 0.2182 
CGM Yes 0 . . . 
Military Rank of Sponsor Enlisted 0.2142 0.05213 4.11 <.0001 
Military Rank of Sponsor Officer 0 . . . 
Period Length 
 
0.000708 0.000095 7.45 <.0001 
Pre-A1c Value 
 
0 . . . 
Differences of Least Squares Means 











Switch 9.1 -0.5723 0.0926 -6.18 <.0001 -0.7538 -0.3907 
Augment 9.1 -0.3076 0.09763 -3.15 0.0016 -0.499 -0.1162 
CSII 9.1 0.0857 0.06038 1.42 0.1558 -0.03266 0.2041 
CGM 9.1 -0.08 0.06493 -1.23 0.2182 -0.2072 0.04732 
Switch 6 0.0201 0.1697 0.12 0.9057 -0.3126 0.3528 
Switch 7 -0.1711 0.1327 -1.29 0.1974 -0.4312 0.08905 
Switch 8 -0.3622 0.1042 -3.48 0.0005 -0.5665 -0.158 
Switch 9 -0.5534 0.09252 -5.98 <.0001 -0.7348 -0.372 
Switch 10 -0.7445 0.1035 -7.19 <.0001 -0.9474 -0.5416 
Switch 11 -0.9357 0.1316 -7.11 <.0001 -1.1937 -0.6777 
Switch 12 -1.1269 0.1684 -6.69 <.0001 -1.4571 -0.7967 
Augment 6 -0.0951 0.1675 -0.57 0.5702 -0.4235 0.2333 
Augment 7 -0.1637 0.13 -1.26 0.208 -0.4185 0.09114 
Augment 8 -0.2323 0.1033 -2.25 0.0246 -0.4348 -0.02972 
Augment 9 -0.3008 0.0969 -3.1 0.0019 -0.4908 -0.1109 
Augment 10 -0.3694 0.1142 -3.23 0.0012 -0.5933 -0.1455 
Augment 11 -0.438 0.1471 -2.98 0.0029 -0.7263 -0.1497 
Augment 12 -0.5066 0.1875 -2.7 0.0069 -0.8741 -0.139 
Appendix Table 4 displays statistical results from the final reduced linear multilevel mixed effects model. 
The intercept for each patient was the sum of the fixed effect (shown above) and the patient-level random 
effect (not shown). Summary information from these data are also displayed in Tables 2, 3 and 4.
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CHAPTER 4: MANUSCRIPT 3 – EMERGENCY CARE 
Abstract 
Purpose: The purpose of this study was to estimate the effects of continuous 
subcutaneous insulin infusion (CSII) and/or continuous glucose monitoring (CGM) on 
emergency care utilization in an observational cohort of pediatric patients with type 1 
diabetes mellitus (T1DM). 
Methods: This study was performed using data extracted from the US Department 
of Defense (DOD) Military Health Systems (MHS) database between October 2007 and 
September 2013. Exploratory analyses were performed to develop an algorithm designed 
to identify diabetic patients and differentiate between type 1 and type 2 diabetes. We 
created a zero-inflated Poisson model to estimate the effects of switching insulin delivery 
method from multiple daily injections (MDI) to CSII and/or augmenting treatment with a 
CGM on emergency care utilization. 
Results: Our study population consisted of 3,138 pediatric patients with T1DM 
using conventional therapy (multiple daily injections and self-monitoring of blood 
glucose). During follow-up, 62.6% (n=1,964) of patients remained on conventional 
therapy and 37.4% (n=1,174) of patients changed treatment. We observed 21,371 total 
emergency care days during 9,940 patient years of follow-up (2.15 total emergency care 
days per patient year). We observed that patients initiating CSII (RR = 0.81; p<0.0001) 
and CGM (RR = 0.88; p<0.0059) experienced a decrease in total emergency care days. 
Patients using both CSII and CGM (RR = 0.85) did not experience added benefit from 
multiple treatments.  
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Conclusion: We found that patients who changed treatment from conventional 
therapy to CSII and/or CGM experienced a statistically significant reduction in the 





Type 1 diabetes mellitus (T1DM) is an autoimmune disease where the insulin 
producing (beta) cells in the pancreas are destroyed. Consequently, T1DM patients lose 
endogenous glycemic control and must attempt to maintain euglycemia manually through 
insulin injection and blood glucose monitoring. Consequences of dysglycemia include 
diabetic ketoacidosis (DKA) and severe hypoglycemia (SH). These acute complications 
of type 1 diabetes frequently result in emergency care
1,2
 and are responsible for nearly 
80% of deaths in the first decade after diagnosis.
3
 
Insufficient insulin and infection are the most common causes of diabetic 
ketoacidosis.
4,5,6 
While patients with high hemoglobin A1c levels are at greater risk for 
DKA,
7
 severe hypoglycemia is associated with a lower A1c,
8
 as well as high glucose 
variability.
9
 SH is also more common among patients with longer duration of diabetes 
because these patients are more likely to exhibit hypoglycemic unawareness.
10
  
Type 1 diabetic patients inject insulin either through multiple daily injections 
(MDI) or continuous subcutaneous insulin infusion (CSII), also known as an insulin 
pump. T1DM patients must also monitor blood glucose levels to inform insulin dosing 
decisions. Glucose monitoring is traditionally done through self-monitoring of blood 
glucose (SMBG), where the patient must prick their finger multiple times daily to take a 
blood glucose reading. Some patients also choose to use a continuous glucose monitor 
(CGM), a device attached to the patient that estimates blood glucose levels by 
continuously reading glucose levels in interstitial fluid using a wire sensor inserted under 
the skin. 
Fewer than one in four US children with T1DM have a hemoglobin A1c less than 
the American Diabetes Association (ADA) recommended value of 7.5%.
11
 Poor glycemic 
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control is largely due to fear of hypoglycemia.
12,13,14 
 atients’ treatment choices play an 
important role in glycemic control as well as the risk of acute complications of diabetes. 
Conventional insulin therapy (CIT) is a treatment regimen characterized as having few 
injections with meals scheduled around peaks in insulin activity. CIT is designed around 
structure, where insulin dosages, meal timing, and carbohydrate load are consistent from 
day to day. Flexible intensive insulin therapy (FIIT) is a newer insulin regimen 
characterized by flexible meal times with frequent injections designed to more 
appropriately adhere to a typical lifestyle. FIIT has been shown to improve hemoglobin 
A1c and reduce the risk of SH and DKA compared to CIT.
15,16  
As CSII became a more popular treatment, many physicians were concerned 
infusion site failures would increase risk of DKA. When infusion of rapid-acting insulin 
stops, insulinopenia develops quickly
17
 and may progress to DKA. However, studies 
suggest there may be decreased risk of ketoacidosis among patients using CSII as well as 
a decreased risk of severe hypoglycemia.
 18,19,20
  
Increased frequency of SMBG has been shown to lower hemoglobin A1c without 
increased risk of SH.
21
 CGM use has been shown to reduce time spent in hypoglycemia.
 
22
 However, evidence of the effectiveness of CGM use at reducing risk of acute 
complications of T1DM is mixed with some studies suggesting a reduction in SH and/or 
DKA
23,24,25
 and some finding no association.
26,27
 
We hypothesized that if CSII and/or CGM reduce the risk of acute complications 
among T1DM patients, it should translate into fewer days spent in emergency care. To 
test this hypothesis, we created a cohort of pediatric patients with type 1 diabetes using 
insurance claims data. All patients had T1DM for at least one year and were using MDI 
92 
 
and SMBG at baseline. The purpose of our study was to estimate changes in the number 




This study was performed using data extracted from the US Department of 
Defense (DOD) Military Health Systems (MHS) database. The DOD MHS serves active 
and past military personnel (known as the sponsor) and their dependents. The database 
includes both an electronic medical record (EMR) and a medical insurance claims 
component. All patients are included in the insurance claims data, and approximately one 
third have EMR data. Data collected includes: demographics, diagnostic codes, 
information on medical procedures, symptoms, vital signs, laboratory and radiology 
results, and pharmacy orders and claims. The crude data, prepared by Health Research Tx 
(HRTx), included all EMR encounters and insurance claims for patients with at least one 
International Classification of Diseases, Ninth Revision (ICD-9) diagnostic code 
indicating diabetes (250.XX) before their 19
th
 birthday. All personal identifiable 
information was removed. At the time of extraction, data were available between October 
2007 and September 2013. 
Patients in the DOD MHS dataset during the study period meeting the following 
criteria were selected for this study: 
 At least one of the following: 
o One hospitalization with an ICD-9 diagnostic code for DM (250.XX) 
o Two DM diagnostic codes within one year 
o One diagnostic code for DM and one treatment for DM 
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 Patient has algorithm defined type 1 diabetes 
 Age 18 years or younger at first diabetes diagnosis 
 A minimum of 18 months of enrollment after first DM diagnosis 
Previous studies,
 28,29
 as well as our own exploratory analyses, have shown that 
glycemic control varies drastically during the first year after type 1 diabetes diagnosis. 
Because we could not perfectly distinguish between incident and prevalent diabetes, we 
required a 12 month baseline period after the first indication of T1DM in the data, and no 
outcomes were measured until completion of the baseline period. Among patients 
meeting the eligibility criteria, the first day after the completion of the baseline period 
was considered the index day for the study. We also required a minimum of 6 months of 
follow-up. These requirements enabled us to create cohort with established, and more 
stable, diabetes and with enough follow-up to observe emergency care utilization. 
Exclusion criteria were chosen to reduce the number of patients with gestational or 
other secondary (non-type 1 or 2) diabetes. Patients also needed to be using conventional 
therapy on the index day so they would be at risk of a treatment change. Patients meeting 
the following criteria were excluded from the study: 
 Patients becoming pregnant less than six months after index date were excluded. 
(Patients becoming pregnant greater than six months after index were censored at 
the pregnancy date.)  
 Patients with an ICD-9 code indicating any of the following: secondary diabetes 
(249.x), other endocrine dysfunction (251.8), adrenal cortical steroids causing 
adverse effects in therapeutic use (E932.0), adenocarcinomas (151.0), lupus 
erythematosus (710.0, 695.4), cystic fibrosis (277.0, 277.0X), hemochromatosis 
(275.0), acromegaly (253.0), Cushing’s syndrome (255.0),  own syndrome 
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(758.0), Klinefelter syndrome (758.7), Turner syndrome (758.6), Huntington 
chorea (333.4), or Laurence-Moon-Biedl syndrome (759.89). 
 Patients using CSII or CGM within one year of first diagnosis 
 
Diabetes Type Algorithm 
Previous studies have shown T1DM diagnostic codes and insulin prescriptions 
can be used to identify pediatric T1DM patients in claims and EMR data with high 
specificity.
30,31,32,33
 Using this information, we performed exploratory data analyses to 
develop an algorithm to differentiate between type 1 and type 2 diabetes in the MHS data. 
To achieve this, we created a cohort of patients with only type 1 (250.x1or 250.x3) or 
with only type 2 (250.x2) ICD-9 diagnostic codes. The characteristics of these patients 
were used to differentiate between diabetes types for those patients where diagnostic 
codes were of mixed type or only included unspecified diabetes (250.00). The final 
differentiating algorithm was: at least two T1DM medication orders on separate days and 
(at least one T1DM diagnostic code or zero T2DM diagnostic codes).  
 
Mode of Diabetic Treatment  
All patients were using conventional therapy (MDI and SMBG) on the index day. 
Patients using CSII or CGM on or before the end of the baseline period were excluded so 
that only patients at risk of both treatment changes remained. For the purposes of this 
study, a treatment “switch” was defined as a change in insulin delivery method from 
multiple daily injections to CSII. An “augment” was defined as initiation of CGM as 
CGM is meant to be used in addition to SMBG. Once a patient initiated CSII and/or 
CGM, they were considered to be using the therapy until the end of follow-up. 
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Measures of Acute Dysglycemia  
We used emergency care days as a measure of acute complications of 
dysglycemia. Patients with severe hypoglycemia frequently require ambulance or 
emergency room services,
34
 and those with DKA are often hospitalized.
35,36
 Therefore, 
we counted all hospitalization days, emergency room/ambulance days, and total 
emergency (hospitalization and/or ER/ambulance) care days during follow-up. These 
counts were the primary outcomes for our analyses.  
By counting hospitalizations and ER/ambulance days separately, we attempted to 
estimate the effect of CSII and CGM on ketoacidosis and severe hypoglycemia separately 
and in total. Total emergency care days was our measure for all acute complications. We 
performed exploratory data analyses to test these assumptions by calculating proportion 
of emergency encounters with any SH (250.12) and DKA (250.1x) ICD-9 diagnostics 
codes (see “Effects of Treatment on Acute Complications of T1DM” in the  iscussion). 
 
Statistical Analyses 
We created means and frequency distributions of patient characteristics to 
describe the study population at study entry. We characterized patients in terms of age, 
gender, BMI on index day, hemoglobin A1c on index day, geographic region, and 
military branch and rank of sponsor.  
The primary outcome of our study was the number of days with emergency care 
in each 6-month time segment. We used zero-inflated Poisson regression to estimate the 
effects of a treatment change on utilization of emergency care. Patient follow-up was 
divided into 6-month periods to allow time for emergency care encounters, and indicator 
variables were created to indicate treatment during each period. Hospitalization days, 
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emergency room/ambulance days, and total emergency (hospitalization and/or 
ER/ambulance) care days were counted during each period. Bivariate, full, and final 
backwards selection models were created to estimate the changes in the number of each 
type of emergency care day (hospital, ER/ambulance, and total) after a switch and/or 
augment. We hypothesized there may be interaction between CSII and CGM use, where 
patients using both may experience a benefit that differs from the sum of each individual 
treatment. Consequently, an interaction term was added to the model and tested for 
significance. Estimates for the effects of CSII and CGM on utilization of emergency care 
were calculated in the form of rate ratios (RRs). 
We also performed a secondary analysis to assess the association between CSII 
and CGM use and utilization of diabetes-related emergency care. In this analysis, only 
emergency care with a diabetes-related (250.XX) primary diagnosis was counted. All 
other aspects of the model were consistent with the primary analysis. 
All statistical analyses were performed on the HRTx Citrix server using SAS 
version 9.3. Summaries from regression analyses of primary outcomes are displayed in 




Our study population consisted of 3,138 individuals including 1,769 males and 
1,369 females. The average age at study entry (after baseline) was 13.8 years old. Among 
patients with EMR data, the average first hemoglobin A1c recording was 9.3% (median: 
9.0%) and the average first BMI measurement was 23.6 kg/m
2





patients were using conventional therapy at study entry. Patient characteristics are 
displayed in Table 1. Patient selection and treatment patterns are displayed in Figure 1. 
 
Treatment Patterns 
During follow-up, 62.6% (n=1,964) of patients remained on conventional therapy, 
while 37.4% (n=1,174) of patients changed treatment. Nearly 90% (n=1,056) of patients 
changing treatment initiated CSII, including 31.9% (n=375) who initiated CSII and 
CGM. Only 3.8% (n=118) of the patients in the cohort augmented with CGM without 
also switching to CSII. Treatment patterns are displayed in Table 2. 
 
Emergency Care Utilization 
The average duration of patient follow-up was 3.2 years, giving a total of 9,940 
patient years for analysis. During this time, we observed 21,371 total emergency care 
days, including 13,986 hospitalization days and 12,858 ER/ambulance days, which 
translates to 1.29 ER/ambulance days, 1.41 hospital days, and 2.15 total emergency care 
days per patient year. On average, in a 6-month period, 28% of patients utilized 
emergency care including 27% with at least one ER or ambulance encounter and 9% with 
a hospitalization. The distributions of average emergency care utilization per 6-month 
period for total emergency care, ER/ambulance care, and hospitalizations are displayed in 
Figures 2, 3, and 4, respectively. DKA was the most common diagnosis for all types of 
emergency care, followed by other ICD-9 codes related to type 1 diabetes. DKA 
diagnostic codes were present in approximately 44% of hospital records, 19% of ER 
records, and 8% of ambulance claims. Hypoglycemia codes were very rare in the data, 
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present in fewer than 2% of ER records, less than 1% of ambulance records, and virtually 
absent in hospitalization records. 
Zero inflated Poisson models consist of two parts, a model for predicting excess 
zeros and a Poisson model. In our final regression model, gender, age, military rank of 
sponsor, and geographic region were associated with zero counts. Female gender 
(RR=1.13; p<0.0001), older age (RR=1.05; p<0.0001), “Enlisted” military rank of 
sponsor (RR=1.12; p<0.0001), and living in the western US (p<0.0001) were all 
associated with increased risk for emergency care utilization. We estimated CSII usage 
decreased hospitalization days (RR=0.75; p<0.0001), ER/ambulance days (RR=0.94; 
p=0.02), and total emergency care days (RR=0.81; p<0.0001). Similarly, patients using a 
CGM demonstrated fewer hospitalization days (RR=0.89; p=0.03), ER/ambulance days 
(RR=0.85; p=0.02), and total emergency care days (RR=0.88; p=0.006). The interaction 
between CSII and CGM was statistically significant in each model, showing reduced 
effectiveness from multiple treatments. Patients using both CSII and CGM spent fewer 
days in the hospital (RR=0.80; p<0.0001) and had fewer total emergency care days 
(RR=0.85; p<0.0001) compared to patients who remained on conventional therapy; 
however, there was no difference in the number of days with an ER/ambulance encounter 
(RR=1.04; p=0.32). Results of the effects of treatment on each type of emergency care 
are displayed in Tables 3 through 5.  
Initiation of CSII, CGM, or both had statistically similar results on the effects of 
total emergency care utilization. The effects of initiating CSII and the effects of initiating 
CGM were not statistically different (p=0.10). Further, initiating CGM after CSII (0.21) 
or CSII after CGM (0.51) added no benefit in the reduction of emergency care. A 
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comparison of effects from each treatment combination on total emergency care is 
displayed in Table 6. 
In our secondary analysis, we estimated CSII use was associated with reduced 
utilization of total emergency care (RR=0.90; p<0.0001) and hospitalization days 
(RR=0.87; p<0.0001); however, CSII was not associated (RR=1.01; p=0.86) with the 
number of days with an ER/ambulance encounter. Patients using a CGM demonstrated 
fewer hospitalization days (RR=0.81; p=0.002), ER/ambulance days (RR=0.88; 
p=0.008), and total emergency care days (RR=0.90; p=0.003). The interaction between 
CSII and CGM was statistically significant for hospitalization days but not for 
ER/ambulance days and total emergency care days. Patients using both CSII and CGM 
experienced fewer days in the hospital (R =0.84; p=0.0001) compared to patients who 
remained on conventional therapy. Results from the secondary analysis are displayed in 
Tables 7 through 9. 
 
Discussion 
Summary of Main Findings 
Our study suggests patients who initiate continuous subcutaneous insulin infusion 
and/or continuous glucose monitoring experience a significant reduction in the utilization 
of emergency care. More than one third of the patients in the cohort changed treatment 
during follow-up. We observed 2.15 total emergency care days per patient year and 
estimated that switching treatment to CSII reduced days utilizing emergency care by 
19%, augmenting with a CGM resulted in a 12% reduction in emergency care days, and 
initiating both CSII and CGM reduced days with emergency care by 15%. CSII was 
associated with a larger reduction in total hospital days, while CGM use was associated 
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with a larger reduction in ER/ambulance care days. All treatment combinations including 
CSII and/or CGM had statistically similar effects. 
 
Treatment Changes and Acute Complications of T1DM 
We hypothesized ambulance and emergency room encounters were more likely to 
capture episodes of severe hypoglycemia, while hospitalizations would be more likely to 
measure ketoacidosis encounters. While this was true, DKA was the most commonly 
recorded diagnostic code for all types of encounters. Furthermore, as prevalent as DKA 
codes were, SH codes were quite rare. This suggests either most episodes of SH occur 
outside of an emergency care setting or SH was poorly recorded in our data (or both). 
Because DKA and SH did not separately correlate well with hospitalization days 
and ER/ambulance days, we are unable to estimate whether patients initiating CSII and/or 
CGM therapy experience reductions in DKA and SH, specifically. However, because we 
observed significant reductions in the number of days with ER/ambulance, 
hospitalization, and total emergency care, we can infer that patients initiating CSII and/or 
CGM do experience a reduction in emergency care utilization. 
 
Emergency Care Days  
Other studies have reported incidence rates of acute complications of T1DM. A 
2008 meta-analysis of clinical trial data estimated the incidence of severe hypoglycemia 
was 36 events per 100 patient years for children and 100 events per 100 patient years for 
adults.
37
 US studies have estimated the rate of DKA among type 1 diabetics to be 8 to 10 
events per 100 patient years;
38,39
 however, hospital admission rates among adolescence 
with poor metabolic control is likely several times higher.
40
 International studies 
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describing incidence of DKA among type 1 diabetics have reported between 5 and 26 
events per 100 patient years.
41,42,43
  
It is an important distinction that we were not directly measuring severe 
hypoglycemia and diabetic ketoacidosis encounters. Instead, we measured emergency 
care days. Moreover, we believed diabetes is sometimes an indirect cause of emergency 
care. Therefore, in our primary analysis we included all emergency care days in our 
analyses instead of limiting to diabetes related emergency care days. It is also important 
to note the difference between measuring the incidence of events, as discussed above, and 
measuring care days, as we did. A Canadian study found average length of diabetes 
related hospital stay is 3.5 days for non-DKA admissions and 3.2 days for DKA-related 
admissions.
44
 Our study was designed to detect differences in emergency care days as a 
result of treatment, which may have been a result of fewer and/or shorter emergency care 
events. However, we were unable to determine if patients in our study experienced a 
reduction in the number of events or fewer days per event (or both).  
The interaction between CSII and CGM showed no added benefit from a second 
treatment. Any combination of treatments including CSII and/or CGM showed a 
statistically significant reduction in the utilization of total emergency care; however, they 
were statistically equivalent to each other. There are several possible explanations for 
this. The most likely explanation is that this effect was due to confounding by indication. 
Patients initiating both CSII and CGM during the study period may have been less 
healthy than their comparators. Consequently, they may have been more likely to utilize 
emergency care. It is also possible that after initiating CSII or CGM patients reach their 
highest achievable level of control so that adding a second therapy is not beneficial. 
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Our secondary analysis restricted emergency care days to encounters with 
diabetes-related diagnostic codes. Interestingly, we found CSII therapy had a larger effect 
on overall emergency care (RR=0.81) than on emergency care directly related to diabetes 
(RR=0.90). The effect of CSII was smaller on diabetes-related hospitalizations 
(RR=0.87) than total hospitalizations (RR=0.75), and there was no association between 
CSII use and diabetes-related ER/ambulance days (RR=1.01). CGM use had a greater 
effect on diabetes-related hospitalization days (RR=0.81) than in total hospitalization 
days (RR=0.89) while the effect on other diabetes-related and total emergency care days 
were similar. These results suggest that CSII and CGM may have a significant impact on 
reducing the need for emergency care in situations where diabetes is secondary to another 
ailment. Though, it is also possible that some emergency care encounters related to 
diabetes were not appropriately coded. 
 
Gender  
Previous studies have reported female T1DM patients have higher healthcare 
costs
45
 and are at higher risk of severe hypoglycemia and diabetic ketoacidosis compared 
to male T1DM patients.
46,47 
The results of our study were consistent with this 
observation. We estimated female gender was associated with 10% more ER/ambulance 




We performed several sensitivity analyses to test the robustness of our results. 
First, we tried using alternative statistical models to see if we would get different results. 
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Estimates from multilevel models assuming a Poisson or binomial distribution were 
similar in magnitude and showed the same patterns to those from the zero-inflated 
Poisson model: CSII had a slightly larger effect compared to CGM for total emergency 
care and hospitalizations and CGM had a larger effect on ER/ambulance care. However, 
in both multilevel models, standard errors were larger than in our zero-inflated models 
resulting in wider confidence intervals and reduced statistical significance. Exploratory 
analyses showed our outcomes were clearly zero-inflated (see Figures 2 through 4), so we 
decided zero-inflated Poisson was the best model for our data.  
We also ran a zero-inflated Poisson model where patients did not have to be using 
conventional therapy at study entry. Patients using CSII or CGM (but not both) at study 
entry were included in this analysis. To account for index therapy, we created indictor 
variables for treatment at study entry. Again, our estimates were very similar to those in 
the main analysis model, only with slightly larger standard errors and inferior model fit 
(higher AIC).  
 
Considerations 
Due to the zero-inflated nature of our data, we decided zero-inflated Poisson 
regression was the best statistical model to analyze counts of emergency care days. We 
ran sensitivity analyses (described above) to determine how the statistical model we 
chose affected our results and observed that estimates between models were similar. The 
main shortfall of zero-inflated regression is it does not account for correlated data. By not 
accounting for correlations from repeated measures within subjects, standard errors are 
underestimated. Consequently, by using zero-inflated regression, we slightly 
overestimated the precision and statistical significance of our estimates. 
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Because patients could experience more than one change in treatment, we could 
not center time periods on a treatment change. Therefore, time periods began on the index 
day, and treatment changes occurred at some point during a given period. This means all 
emergency care days experienced in a period included a change in treatment were 
analyzed as if they occurred after the treatment change even if they occurred beforehand. 
This could have biased our estimates towards no association if emergency care 
encounters motivate patients to initiate CSII or CGM shortly thereafter. We performed a 
sensitivity analysis to see how our estimates would be different if treatment changes 
occurring after the midpoint of a period were not counted until the next period. We found 
this had little effect on our estimates (see Table 10).  
We only included T1DM patients with at least one year of diabetes in our 
analyses. Therefore, we were unable to measure the effects of CSII and CGM among 
patients who chose these treatments quickly after diagnosis. It is possible early adapters 
could have experienced different treatment effects than those observed in our study. 
This study was completed using EMR and insurance claims data, which has 
several strengths and limitations. Electronic data are readily available, and a cost and 
time efficient way to measure outcomes for large cohorts of patients. Also, using claims 
data to describe treatment patterns of T1DM patients should capture nearly all insulin, 
CSII, and CGM related purchases as these treatments are expensive and unlikely to be 
paid for out of pocket.  
There was likely some misclassification of diabetes type. Identification of patients 
with T1DM was based on algorithms developed during exploratory data analyses. It is 
possible, however, that some T1DM patients were missed and some T2DM patients were 
wrongfully included. Omission of T1DM patients may have reduced statistical power and 
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could possibly have resulted in selection bias. Our differentiating algorithm was designed 
to be specific (rather than sensitive), so we believe it is unlikely that many patients with 
T2DM were wrongfully classified as type 1.  
Another limitation of EMR/claims data is the lack of information on important 
confounders. For example, we were unable to adjust for sociodemographic indicators, 
including race and ethnicity, in our analyses because this information was missing for 
more than 99% of patients. However, evidence from the literature suggests patient 
sociodemographics may not be a strong confounder for this analysis. By definition, a 
confounder must be independently associated with an outcome and its exposure. Though 
race has been correlated with increased risk of acute complications of type 1 diabetes (the 
outcome),
48
 so has lower socioeconomic status.
49
 Studies have also shown socioeconomic 
characteristics, such as higher education and income, are superior predictors of CSII and 
CGM use (the exposure).
50,51,52
 While we did not have household income or education 
data, we were able to use military rank of sponsor in our analysis, which we believed 
could be a socioeconomic indicator. We observed a strong relationship between 
increasing military rank of sponsor and increased likelihood of CSII/CGM use, which 
supports the hypothesis that sponsor rank may be a socioeconomic indicator. 
Body mass index (BMI) and hemoglobin A1c were not included in the analysis 
because they were not available for every patient. Only 48% of our patients had at least 
one BMI measurement during follow-up, and only 34% of patients had a hemoglobin 
A1c measurement. We performed a post hoc analysis to determine if BMI and 
hemoglobin A1c would have made a meaningful difference in our estimates. Both BMI 
(p=0.0024) and hemoglobin A1c (p<0.0001) were statistically significantly associated 
with total emergency care days. In models where BMI and hemoglobin A1c were 
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included, estimates of reductions in emergency care utilization after initiation of CSII 
and/or CGM were increased. However, we decided not to include BMI and hemoglobin 
A1c in our final models for three reasons. First, and most importantly, our analysis plan a 
priori was to use only claims data. Second, the results displayed in our analyses represent 
more conservative estimates (smaller reductions in emergency care utilization after a 
treatment change). Finally, we would have had to exclude nearly two-thirds of the 
patients in our study, resulting in a substantial loss of power and an increased chance for 
selection bias. 
T1DM patients identified in this study may not be representative of the general 
pediatric T1DM population in the United States. As the dependents of active and past 
military personnel, patients in this study are likely demographically different than the 
general US pediatric population and likely experience different levels of healthcare. 
However, we have no reason to believe that the treatment effects described in our study 
would vary greatly among different populations. 
 
Conclusion 
The purpose of this study was to estimate the effects of continuous subcutaneous 
insulin infusion and continuous glucose monitoring on utilization of emergency care in an 
observational cohort of pediatric patients with type 1 diabetes. Patients in our study 
experienced, on average, approximately two emergency care days annually. We found 
that patients initiating CSII and/or CGM experienced a statistically significant reduction 
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Gender [n (%)] 
 
    Female 1369 (43.6%) 
    Male 1769 (56.4%) 
Age [mean (SD)] 13.8 (3.6) 
Patients with Index BMI Value [n (%)] 1515 (48.3%) 
    Body Mass Index [mean (SD)] 23.6 (5.2) 
Patients with Index HbA1c Value [n (%)] 1076 (34.3%) 
    Hemoglobin A1c [mean (SD)] 9.3 (2.3) 
Military branch [n (%)] 
 
    Army 1249 (39.8%) 
    Coast Guard 69 (2.2%) 
    Air Force 815 (26.0%) 
    Marine Corps 221 (7.0%) 
    Navy 768 (24.5%) 
    Other 16 (0.5%) 
Geographic region [n (%)] 
 
    West 373 (11.9%) 
    Central 438 (14.0%) 
    Northeast 1154 (36.8%) 
    Southeast 968 (30.8%) 
    Alaska/Hawaii 113 (3.6%) 
    Non-US 92 (2.9%) 
Rank of Sponsor [n (%)] 
 
    Enlisted, Junior 236 (7.5%) 
    Enlisted, Senior 2297 (73.2%) 
    Warrant Officer 82 (2.6%) 
    Officer, Junior 134 (4.3%) 
    Officer, Senior 388 (12.4%) 
    Other 1 (0.0%) 
 




Patients with No Treatment Change 1,964 (62.6%) 
Patients with Treatment Change 1,174 (37.4%) 
Patients with Switch to CSII Only 681 (58.0%) 
Patients with Augment with CGM Only 118 (10.1%) 
Patients with Switch and Augment 375 (31.9%) 
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Table 3: Effect of CSII and CGM on Total Emergency Care Days (n=3,138). 
Effect 
Model 
Bivariate Full Final* 
RR (95% C.L.) p-value RR (95% C.L.) p-value RR (95% C.L.) p-value 
CSII 0.77 (0.74, 0.80) <0.0001 0.81 (0.78, 0.84) <0.0001 0.81 (0.78, 0.84) <0.0001 
CGM 0.84 (0.80, 0.89) <0.0001 0.89 (0.81, 0.97) 0.01 0.88 (0.80, 0.96) 0.006 
CSII*CGM Interaction N/A 
 
1.18 (1.05, 1.32) 0.007 1.19 (1.06, 1.34) 0.003 
CSII and CGM N/A  0.84 (0.79, 0.90) <0.0001 0.85 (0.79, 0.90) <0.0001 
RR: Rate Ratio 
*The final Zero Inflated Poisson regression model was adjusted for gender, age, military rank of sponsor, and geographic region, and the zero-model was adjusted for 
gender, age, military rank of sponsor, and geographic region. Detailed statistical results are displayed in Appendix Table 2. 
 
Table 4: Effect of CSII and CGM on Hospitalization Days (n=3,138). 
Effect 
Model 
Bivariate Full Final* 
RR (95% C.L.) p-value RR (95% C.L.) p-value RR (95% C.L.) p-value 
CSII 0.72 (0.69, 0.75) <0.0001 0.75 (0.71, 0.78) <0.0001 0.75 (0.71, 0.78) <0.0001 
CGM 0.82 (0.77, 0.87) <0.0001 0.89 (0.79, 0.99) 0.03 0.89 (0.79, 0.99) 0.03 
CSII*CGM Interaction N/A 
 
1.21 (1.05, 1.39) 0.008 1.21 (1.05, 1.40) 0.008 
CSII and CGM N/A  0.80 (0.74, 0.87) <0.0001 0.80 (0.74, 0.87) <0.0001 
RR: Rate Ratio 
*The final Zero Inflated Poisson regression model was adjusted for gender, age, military branch of sponsor, and geographic region, and the zero-model was adjusted for 





Table 5: Effect of CSII and CGM on ER/Ambulance Days (n=3,138). 
Effect 
Model 
Bivariate Full Final* 
RR (95% C.L.) p-value RR (95% C.L.) p-value RR (95% C.L.) p-value 
CSII 0.85 (0.81, 0.89) <0.0001 0.93 (0.88, 0.99) 0.02 0.94 (0.88, 0.99) 0.02 
CGM 0.89 (0.82, 0.96) 0.002 0.84 (0.73, 0.97) 0.02 0.85 (0.75, 0.97) 0.02 
CSII*CGM Interaction N/A 
 
1.34 (1.12, 1.59) 0.001 1.31 (1.11, 1.54) 0.001 
CSII and CGM N/A  1.04 (.96, 1.14) 0.28 1.04 (0.96, 1.13) 0.32 
RR: Rate Ratio 
*The final Zero Inflated Poisson regression model was adjusted for gender, age, military branch of sponsor, military rank of sponsor, and geographic region, and the zero-





Table 6: Comparison of Treatment Effects (n=3,138). 
Comparison RR p-value 
CSII and SMBG vs. MDI and SMBG 0.81 <0.0001 
MDI and CGM vs. MDI and SMBG 0.88 0.006 
CSII and CGM vs. MDI and SMBG 0.85 <0.0001 
CSII and SMBG vs. MDI and CGM 0.92 0.10 
CSII and CGM vs. MDI and CGM 0.96 0.51 
CSII and CGM vs. CSII and SMBG 1.05 0.21 
Table 6 displays a comparison of treatment effects from all treatment combinations of multiple 
daily injections (MDI), self-monitoring of blood glucose (SMBG), continuous subcutaneous 




Table 7: Effect of CSII and CGM on Diabetes Related Total Emergency Care Days (n=3,138). 
Effect 
Model 
Bivariate Full Final* 
RR (95% C.L.) p-value RR (95% C.L.) p-value RR (95% C.L.) p-value 
CSII 0.83 (0.79, 0.86) <0.0001 0.90 (0.85, 0.94) <0.0001 0.90 (0.86, 0.94) <0.0001 
CGM 0.81 (0.76, 0.86) <0.0001 0.90 (0.80, 1.01) 0.07 0.90 (0.84, 0.97) 0.003 
CSII*CGM Interaction N/A  N/A 0.65 N/A 0.43 
RR: Rate Ratio 
*The final Zero Inflated Poisson regression model was adjusted for gender, age, military rank of sponsor, and geographic region, and the zero-model was adjusted for 
gender, age, military rank of sponsor, and geographic region. Detailed statistical results are displayed in Appendix Table 5. 
 
Table 8: Effect of CSII and CGM on Diabetes Related Hospitalization Days (n=3,138). 
Effect 
Model 
Bivariate Full Final* 
RR (95% C.L.) p-value RR (95% C.L.) p-value RR (95% C.L.) p-value 
CSII 0.80 (0.76, 0.83) <0.0001 0.87 (0.83, 0.92) <0.0001 0.87 (0.83, 0.92) <0.0001 
CGM 0.77 (0.72, 0.83) <0.0001 0.80 (0.70, 0.92) 0.001 0.81 (0.71, 0.92) 0.002 
CSII*CGM Interaction N/A  1.19 (1.01, 1.41) 0.04 1.18 (1.01, 1.40) 0.049 
CSII and CGM N/A  0.83 (0.76, 0.92) 0.0002 0.84 (0.76, 0.92) 0.0001 
RR: Rate Ratio 
*The final Zero Inflated Poisson regression model was adjusted for gender, age, military branch of sponsor, and geographic region, and the zero-model was adjusted for 





Table 9: Effect of CSII and CGM on Diabetes Related ER/Ambulance Days (n=3,138). 
Effect 
Model 
Bivariate Full Final* 
RR (95% C.L.) p-value RR (95% C.L.) p-value RR (95% C.L.) p-value 
CSII 0.87 (0.81, 0.92) <0.0001 1.01 (0.95, 1.08) 0.72 1.01 (0.94, 1.07) 0.86 
CGM 0.74 (0.67, 0.82) <0.0001 0.85 (0.77, 0.95) 0.003 0.88 (0.80, 0.97) 0.008 
CSII*CGM Interaction N/A  N/A 0.99 N/A 0.84 
RR: Rate Ratio 
*The final Zero Inflated Poisson regression model was adjusted for gender, age, military rank of sponsor, and geographic region, and the zero-model was adjusted for 






Table 10: Comparison of Main Analysis and Midpoint Sensitivity Analysis 
(n=3,138). 
Treatment 
Main Analysis Midpoint Analysis 
RR (95% C.L.) p-value RR (95% C.L.) p-value 
CSII 0.81 (0.78, 0.84) <0.0001 0.76 (0.73, 0.79) <0.0001 
CGM 0.88 (0.80, 0.96) 0.006 0.91 (0.83, 1.005) 0.06 
CSII*CGM Interaction 1.19 (1.06, 1.34) 0.003 1.14 (1.01, 1.30) 0.03 
CSII and CGM 0.85 (0.79, 0.90) <0.0001 0.79 (0.74, 0.85) <0.0001 








Figure 2: Histogram of total emergency care (n=3,138). 
 





Figure 3: Histogram of hospitalizations (n=3,138). 
 






Figure 4: Histogram of ER/ambulance care (n=3,138). 
 











    Patient has a DM Dx 13,977 (100.0%) 
 
    Patient has sufficient DM Dx/med criteria 9,610 (68.8%) 4,367 (31.2%) 
    Patient has algorithm defined T1DM 6,691 (47.9%) 2,919 (20.9%) 
    Patient was less than 18 years old at the time of first diagnosis 6,690 (47.9%) 1 (0.0%) 
    Patient has sufficient follow-up (18 months) enrollment 5,596 (40.0%) 1,094 (7.8%) 
    Patient not excluded for pregnancy 5,483 (39.2%) 113 (0.8%) 
    Patient not excluded for condition Dx 5,101 (36.5%) 382 (2.7%) 
    Patient is at risk of switch and augment 3,138 (22.5%) 1,963 (14.0%) 
Appendix Table 1 displays the number of patients excluded and the number of patient remaining after each 




Table A2: Effect of CSII and CGM on Total Emergency Care Days – Final Model 
(n=3,138). 
Parameter Level RR (95% C.L.) p-value 
CSII 
 
0.81 (0.78, 0.84) <.0001 
CGM 
 
0.88 (0.80, 0.96) 0.006 
CSII*CGM Interaction 
 
1.19 (1.06, 1.34) 0.003 
Gender Male vs. Female 0.89 (0.86, 0.91) <.0001 
Age 1 year 1.05 (1.04, 1.05) <.0001 
Rank of Sponsor Officer v. Enlisted 0.89 (0.85, 0.93) <.0001 
Region Alaska/Hawaii 0.78 (0.72, 0.85) <.0001 
Region Central 0.71 (0.67, 0.75) <.0001 
Region Non-US 0.93 (0.85, 1.03) 0.15 
Region Northeast 0.84 (0.80, 0.87) <.0001 
Region Southeast 0.68 (0.65, 0.71) <.0001 
Region West Ref. 
 
Appendix Table 2 displays statistical results from our final Zero-Inflated Poisson Regression on the effects 
of continuous subcutaneous insulin infusion (CSII) and/or continuous glucose monitoring (CGM) on total 
emergency care days. A summary of these data are also displayed in Tables 3 and 10.  






Table A3: Effect of CSII and CGM on Hospitalization Days – Final Model (n=3,138). 
Parameter Level RR (95% C.L.) p-value 
CSII 
 
0.75 (0.71, 0.78 <.0001 
CGM 
 
0.89 (0.79, 0.99 0.03 
CSII*CGM Interaction 
 
1.21 (1.05, 1.40 0.008 
Gender Male vs. Female 0.93 (0.90, 0.96 <.0001 
Age 1 year 1.03 (1.03, 1.04 <.0001 
Military Branch Air Force 1.83 (1.22, 2.75 0.004 
Military Branch Army 1.79 (1.19, 2.69 0.005 
Military Branch Coast Guard 1.59 (1.04, 2.43 0.03 
Military Branch Marine Corps 2.06 (1.37, 3.12 0.0006 
Military Branch Navy 2.04 (1.35, 3.07 0.0007 
Military Branch Other Ref. 
 
Region Alaska/Hawaii 0.86 (0.78, 0.95 0.003 
Region Central 0.84 (0.79, 0.90 <.0001 
Region Non-US 0.91 (0.81, 1.01 0.08 
Region Northeast 0.91 (0.87, 0.96 0.0003 
Region Southeast 0.69 (0.66, 0.73 <.0001 
Region West Ref. 
 
Appendix Table 3 displays statistical results from our final Zero-Inflated Poisson Regression on the effects 
of continuous subcutaneous insulin infusion (CSII) and/or continuous glucose monitoring (CGM) on 
hospitalization days. A summary of these data are also displayed in Table 4.  






Table A4: Effect of CSII and CGM on ER/Ambulance Days – Final Model (n=3,138). 
Parameter Level RR (95% C.L.) p-value 
CSII 
 
0.94 (0.88, 0.99) 0.02 
CGM 
 
0.85 (0.75, 0.97) 0.02 
CSII*CGM Interaction 
 
1.31 (1.11, 1.54) 0.001 
Gender Male vs. Female 0.91 (0.87, 0.94) <.0001 
Age 1 year 1.08 (1.07, 1.08) <.0001 
Military Branch Air Force 0.82 (0.53, 1.25) 0.35 
Military Branch Army 0.78 (0.51, 1.19) 0.24 
Military Branch Coast Guard 0.50 (0.32, 0.80) 0.004 
Military Branch Marine Corps 0.68 (0.44, 1.05) 0.09 
Military Branch Navy 0.85 (0.55, 1.30) 0.45 
Military Branch Other Ref. 
 
Rank of Sponsor Officer v. Enlisted 0.67 (0.63, 0.72) <.0001 
Region Alaska/Hawaii 0.69 (0.61, 0.79) <.0001 
Region Central 0.66 (0.60, 0.72) <.0001 
Region Non-US 0.50 (0.41, 0.60) <.0001 
Region Northeast 0.89 (0.84, 0.95) 0.0002 
Region Southeast 0.93 (0.87, 0.99) 0.03 
Region West Ref. 
 
Appendix Table 4 displays statistical results from our final Zero-Inflated Poisson Regression on the effects 
of continuous subcutaneous insulin infusion (CSII) and/or continuous glucose monitoring (CGM) on 
ER/ambulance care days. A summary of these data are also displayed in Table 5.  






Table A5: Effect of CSII and CGM on Diabetes-Related Emergency Care Days – Final 
Model (n=3,138). 
Parameter Level RR (95% C.L.) p-value 
CSII 
 
0.90 (0.86, 0.94) <.0001 
CGM 
 
0.90 (0.84, 0.97) 0.003 
Gender Male vs. Female 0.92 (0.89, 0.95) <.0001 
Age 1 year 1.04 (1.04, 1.05) <.0001 
Rank of Sponsor Officer v. Enlisted 0.82 (0.78, 0.87) <.0001 
Region Alaska/Hawaii 0.92 (0.83, 1.03) 0.14 
Region Central 0.88 (0.82, 0.94) <.0001 
Region Non-US 1.35 (1.22, 1.51) <.0001 
Region Northeast 0.92 (0.87, 0.97) 0.001 
Region Southeast 0.75 (0.71, 0.79) <.0001 
Region West Ref. 
 
Appendix Table 5 displays statistical results from our final Zero-Inflated Poisson Regression on the effects 
of continuous subcutaneous insulin infusion (CSII) and/or continuous glucose monitoring (CGM) on 
diabetes-related total emergency care days. A summary of these data are also displayed in Table 7. 





Table A6: Effect of CSII and CGM on Diabetes-Related Hospitalization Days – Final 
Model (n=3,138). 
Parameter Level RR (95% C.L.) p-value 
CSII 
 
0.87 (0.83, 0.92) <.0001 
CGM 
 
0.81 (0.71, 0.92) 0.002 
CSII*CGM Interaction 
 
1.18 (1.00, 1.40) 0.049 
Gender Male vs. Female 0.97 (0.93, 1.01) 0.10 
Age 1 year 1.04 (1.03, 1.04) <.0001 
Military Branch Air Force 1.68 (1.12, 2.53) 0.01 
Military Branch Army 1.68 (1.12, 2.54) 0.01 
Military Branch Coast Guard 1.13 (0.72, 1.75) 0.60 
Military Branch Marine Corps 1.66 (1.09, 2.51) 0.018 
Military Branch Navy 2.11 (1.40, 3.19) 0.0004 
Military Branch Other Ref. 
 
Region Alaska/Hawaii 1.10 (0.98, 1.23) 0.10 
Region Central 1.18 (1.10, 1.28) <.0001 
Region Non-US 1.28 (1.14, 1.44) <.0001 
Region Northeast 1.08 (1.02, 1.14) 0.01 
Region Southeast 0.86 (0.80, 0.91) <.0001 
Region West Ref. 
 
Appendix Table 6 displays statistical results from our final Zero-Inflated Poisson Regression on the effects 
of continuous subcutaneous insulin infusion (CSII) and/or continuous glucose monitoring (CGM) on 
diabetes-related hospitalization days. A summary of these data are also displayed in Table 8.  






Table A7: Effect of CSII and CGM on Diabetes-Related ER/Ambulance Days – Final 
Model (n=3,138). 
Parameter Level RR (95% C.L.) p-value 
CSII 
 
1.01 (0.94, 1.07) 0.86 
CGM 
 
0.88 (0.80, 0.97) 0.008 
Gender Male vs. Female 0.88 (0.84, 0.93) <.0001 
Age 1 year 1.08 (1.07, 1.09) <.0001 
Rank of Sponsor Officer v. Enlisted 0.66 (0.60, 0.72) <.0001 
Region Alaska/Hawaii 0.63 (0.53, 0.75) <.0001 
Region Central 0.70 (0.63, 0.77) <.0001 
Region Non-US 0.51 (0.40, 0.65) <.0001 
Region Northeast 0.90 (0.84, 0.98) 0.01 
Region Southeast 1.01 (0.93, 1.09) 0.85 
Region West Ref  
Appendix Table 7 displays statistical results from our final Zero-Inflated Poisson Regression on the effects 
of continuous subcutaneous insulin infusion (CSII) and/or continuous glucose monitoring (CGM) on 
diabetes-related ER/ambulance care days. A summary of these data are also displayed in Table 9.  
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CHAPTER 5: SUMMARY AND CONCLUSIONS 
Summary 
Patient Characteristics  
At the time of type 1 diabetes mellitus (T1DM) presentation, 59.2% of patients 
were admitted to the emergency room and 65.3% were hospitalized. The average BMI at 
first diagnosis was 20.1 kg/m
2
. Females were more likely to use continuous subcutaneous 
insulin infusion (CSII) and continuous glucose monitoring (CGM); however, once a 
patient switched to CSII, males and females were equally likely to subsequently add 
CGM. Females also experienced more ER/ambulance and hospitalization days compared 
to males. Increased military rank of sponsor, our socio-economic surrogate, was 
associated with increased CSII and CGM use as well as fewer ER/ambulance, 
hospitalization days, and total emergency care. 
 
Treatment Patterns 
We found the vast majority of incident T1DM patients in our cohort (Aim 1) were 
using conventional therapy (96.3%) three months after diabetes presentation. More than 
half (57.14%) of these patients switched insulin delivery from MDI to CSII and about a 
third (32.62%) augmented with a CGM during follow-up. Greater than 80% of patients 
who used a CGM initiated CSII concurrently or before CGM use. We found female 
gender, higher military rank of sponsor, and living in the Central US were the strongest 
predictors of a treatment switch or augment. We did not detect any changes in CSII use 
over calendar time (p=0.78); however, there was a very strong relationship between 
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calendar year of diagnosis and CGM use (p<0.0001) showing an increased prevalence in 
CGM use with each subsequent year. 
 
Hemoglobin A1c 
The average hemoglobin A1c measurement for patients in Aim 1 was 8.81%. 
However, we found values varied wildly during the first 12 to 14 months after first 
diagnosis. We created a Lowess plot of hemoglobin A1c over time that clearly showed 
the effects of uncontrolled hyperglycemia at presentation followed by a “honeymoon 
period” of increased glycemic control. The plot predicted a decrease in hemoglobin A1c 
from 12.2% at index to 7.2% three months later. Average hemoglobin A1c values then 
steadily increased until stabilizing at around 8.7% approximately one year after 
presentation. The average hemoglobin A1c after the first year of diabetes was 8.71%.  
In Aim 2, we estimated that patients who switched insulin delivery from MDI to 
CSII and/or augmented SMBG with CGM experienced statistically significant reductions 
in hemoglobin A1c at the next measurement. We hypothesized a priori that patients who 
used both CSII and CGM may experience a benefit from both treatments different than 
the additive benefit of each, but tests for interaction between the two treatments were not 
statistically significant. However, we did find an interaction between initial hemoglobin 
A1c and change in treatment so that every 1% increase in A1c above 6% was associated 
with a 0.19% greater reduction in A1c from a switch and a 0.07% greater reduction from 
an augment. Thus we predicted clinically meaningful reductions in hemoglobin A1c after 




Emergency Care Utilization 
In our final analysis (Aim 3), patients utilized 1.29 ER/ambulance days, 1.41 
hospital days, and 2.15 total emergency care days per year of follow-up. We estimated 
that patients who switched from MDI to CSII experienced a decrease in ER/ambulance 
days (RR = 0.94; p<0.0225), hospitalization days (RR = 0.75; p<0.0001), and total 
emergency care days (RR = 0.81; p<0.0001). Patients who initiated CGM also had fewer 
ER/ambulance days (RR = 0.85; p<0.0196), hospitalization days (RR = 0.89; p<0.0306), 
and total emergency care days (RR = 0.88; p<0.0059). The interaction between CSII and 
CGM usage was statistically significant in each model, suggesting that patients using 
CSII and CGM experienced no additional benefit over using CSII (with SMBG) or CGM 
(with MDI). Our secondary analysis showed CSII and CGM use may play an important 
role in reducing utilization of emergency care in circumstances where diabetes is 
secondary to another ailment as well as in diabetes-related situations. 
 
Conclusions  
A Brief History of Diabetes 
Before the discovery of insulin and its subsequent commercialization as a drug, a 
diagnosis of type 1 diabetes was equivalent to a death sentence. The characteristics of 
diabetes were described in Egyptian manuscripts as early as 1500 B.C.
1
 Ancient Indian 
physicians observed ants were attracted to the urine of diabetic patients, thus naming the 
condition, Madhumeha, meaning “sweet urine disease.”
2
 The first recorded description 
using the term ‘diabetes,’ which literally translates from Greek to mean “siphon,” was 
written in the second century A.D. by Aretaus of Cappodocia who described the disease 
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as a “melting down of the flesh and limbs into urine.”
3
 The term ‘mellitus,’ which means 
“sweet like honey,” was coined in 17
th
 century by British physician Tomas Willis to 
distinguish diabetes mellitus from diabetes insipidus, where the urine is not sweet.
4,5
 
Though the sweetness of diabetic urine had been observed for millennia, it was 1775 
before glucose was discovered in the urine of diabetic patients.
6
 In 1889, Joseph Freiherr 
von Mering and his colleagues were able to show for the first time that diabetes was a 
disease of the pancreas by demonstrating that removing the pancreas from dogs 
subsequently resulted in diabetes.
7
  
In the early 1900’s the only treatment for diabetes was a starvation diet,
8
 and the 
life expectancy of a juvenile patient diagnosed with diabetes was only 1.3 years.
9
 In 
1921, Banting and Best were the first to successfully isolate “pancreatic extracts” which 
were shown to reverse ketoacidosis in dogs.
10
 The following year, they published a paper 
describing the successful treatment of seven human patients with type 1 diabetes
11
 
marking a turning point where T1DM was a treatable disease for the first time. By 1923, 
Eli Lilly & Co was producing the first commercially available insulin product, called 
‘Iletin.’ The same year, the Nobel Prize in Physiology or Medicine was awarded to 
Banting (and Macleod), who shared the prize with Best.  
Despite the improvements in insulin extraction and the standardization of therapy 
in the following decades, outcomes for type 1 diabetic patients continued to be poor. A 
study published in 1975 estimated the life expectancy of a person diagnosed with type 1 
diabetic was reduced by 27 years;
12
 though, more recent data has shown life expectancy 
during this time period was rapidly improving. A 2012 study showed type 1 diabetic 
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patients diagnosed between 1965 and 1980 had 15 years longer life expectancy compared 
to patients diagnosed between 1950 and 1964.
13
 
The 1970’s brought several noteworthy improvements in diabetes care including 
the first commercially available glucose meter (the Ames Reflectance Meter),
14
 the first 
insulin pumps,
15,16
 and characterization of hemoglobin A1c as a biomarker for glycemic 
control.
17,18
 Until the early 1980’s, insulin was derived from pork and beef pancreatic 
extracts. In 1983, human insulin produced by E. coli became the first commercially 
available recombinant DNA product. Human recombinant DNA insulin had several 
advantages over animal extracted insulin including improved pharmacokinetics and 
pharmacodynamics and a more reliable and sustainable supply.
19
 
The Diabetes Control and Complications Trial (DCCT) began enrolling patients 
in 1983 among increasing evidence suggesting that improved glycemic control reduced 
the risk of microvascular complications from diabetes.
20
 The 10-year study showed 
conclusively that intensive insulin therapy delayed onset and slowed progression of 
retinopathy and nephropathy in a cohort of type 1 diabetic patients, and these benefits 
outweighed the observed increased risk of severe hypoglycemia.
21
 Results from the 
DCCT provided the first strong evidence that the chronic complications of T1DM were 
not inevitable, but could be prevented or delayed with tight glycemic control. 
 
Type 1 Diabetes Today 
Many of the tools currently used to treat T1DM were developed in the last two 
decades. The rapid-acting (Aspart, Lispro, and Glulisine) and long-acting (Detemir and 
Glargine) insulins commonly used today were developed in the late 1990’s and early 
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2000’s. Continuous glucose monitors became available to physicians in the early 2000’s 
and available for personal patient use beginning in 2006. Insulin pumps have also 
continued to improve and have begun to integrate with CGM technology. Life 
expectancy continues to increase as a result of improved treatment and management of 
complications.
22
 A Scotish study in 2012 estimated current life expectancy for type 1 




Significance of Findings 
Type 1 diabetic patients have more treatment options today than ever before. 
Many continue to use conventional therapy, while others choose CSII and/or CGM 
therapy. However, the treatment patterns of pediatric patients are largely unknown and 
the benefits of CSII and CGM remain unclear. The purpose of this dissertation was to use 
observational data to first describe treatment patterns among pediatric patients and then to 
create estimates of the effects of CSII and CGM use on glycemic control and emergency 
care utilization. The second and third Aims were designed to answer the question: Do 
patients who initiate CSII and/or CGM in a typical care setting experience subsequent 
improvements in glycemic control? 
Systematic reviews and meta-analyses on CSII and CGM, based largely on 
clinical trial data, have shown only modest improvements in hemoglobin A1c except 
among patients with the poorest control.
24,25,26,27,28
 By using claims and EMR data, we 
were able to estimate changes in glycemic control after initiation of CSII and/or CGM 
among real-world patients who chose to use these treatments. Where clinical trials 
estimate true treatment effects, we were estimating the actualized benefits patients 
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experienced from these treatments. It is noteworthy that we measured greater reductions 
in hemoglobin A1c after initiation of CSII and/or CGM than have generally been 
described in clinical trials. Consistent with clinical trials, we found that patients with 
poorer control experienced greater reductions in hemoglobin A1c after a treatment 
change. It may be that we observed more meaningful improvements in hemoglobin A1c 
because patients in our cohort had, on average, poorer glycemic control compared to 
patients included in trials. However, it is also likely that factors which motivated patients 
in our study to initiate a new therapy also affected subsequent changes in hemoglobin 
A1c.  
Studies suggest a decreased risk of diabetic ketoacidosis (DKA) and severe 
hypoglycemia (SH) among patients using CSII.
29,30,31
 Patients using CGM spend less 
total time in hypoglycemia,
32
 but, the evidence of the effectiveness of CGM use at 
reducing risk of acute complications of T1DM is mixed. Some studies have shown 
reduced risk of DKA and/or SH,
33,34,35
 while others have found no association.
36,37
 We 
were unable to distinguish between DKA and SH events in our study. However, we 
estimated a significant reduction in the number of days utilizing emergency care among 
patients who changed from conventional therapy to CSII and/or CGM suggesting a 
meaningful reduction in acute complications from diabetes. 
The American Diabetes Association recommends pediatric patients maintain a 
hemoglobin A1c of 7.5% or less,
38
 but currently, fewer than one in four US children are 
meeting this goal,
39
 largely due to fear of hypoglycemia.
 40,41,42 
The results of our analyses 
suggest patients with poor glycemic control using conventional therapy are likely to 
experience clinically meaningful improvements in hemoglobin A1c as well as fewer 
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acute complications after a change in treatment. We believe patients using traditional 
therapy and not achieving the ADA hemoglobin A1c goal of 7.5% should consider a 
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